Trial Outcomes & Findings for Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (NCT NCT04886596)
NCT ID: NCT04886596
Last Updated: 2025-07-31
Results Overview
First episode of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated LRTD during the first season was assessed. The case definition for RSV-confirmed LRTD is as follows: Presence of at least one RSV-positive swab detected by RT-PCR.
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
26675 participants
Primary outcome timeframe
From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]
Results posted on
2025-07-31
Participant Flow
Out of 26675 participants enrolled in the study, 24972 received study intervention and were included in the Exposed set and started the study.
Participant milestones
| Measure |
RSVPreF3 Group
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
|---|---|---|
|
Overall Study
STARTED
|
12469
|
12503
|
|
Overall Study
RSV_1_dose
|
6226
|
0
|
|
Overall Study
RSV_annual
|
6243
|
0
|
|
Overall Study
COMPLETED
|
9365
|
9361
|
|
Overall Study
NOT COMPLETED
|
3104
|
3142
|
Reasons for withdrawal
| Measure |
RSVPreF3 Group
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
|---|---|---|
|
Overall Study
Adverse Event
|
442
|
441
|
|
Overall Study
Lost to Follow-up
|
448
|
465
|
|
Overall Study
Consent withdrawal, not due to a (S)AE
|
1715
|
1726
|
|
Overall Study
Migrated/moved from the study area
|
201
|
184
|
|
Overall Study
Other
|
298
|
326
|
Baseline Characteristics
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
Baseline characteristics by cohort
| Measure |
RSVPreF3 Group
n=12469 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12503 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
Total
n=24972 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
69.5 YEARS
STANDARD_DEVIATION 6.5 • n=5 Participants
|
69.6 YEARS
STANDARD_DEVIATION 6.4 • n=7 Participants
|
69.5 YEARS
STANDARD_DEVIATION 6.5 • n=5 Participants
|
|
Sex: Female, Male
Female
|
6489 Participants
n=5 Participants
|
6429 Participants
n=7 Participants
|
12918 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
5980 Participants
n=5 Participants
|
6074 Participants
n=7 Participants
|
12054 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian
|
953 Participants
n=5 Participants
|
956 Participants
n=7 Participants
|
1909 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
1064 Participants
n=5 Participants
|
1101 Participants
n=7 Participants
|
2165 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White
|
9889 Participants
n=5 Participants
|
9936 Participants
n=7 Participants
|
19825 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
All Other Races
|
55 Participants
n=5 Participants
|
41 Participants
n=7 Participants
|
96 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Other
|
508 Participants
n=5 Participants
|
469 Participants
n=7 Participants
|
977 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]Population: Analysis was performed on the modified Exposed Set (mES), which included all participants who received at least the first dose of the study intervention and who do not report an RSV-confirmed Acute Respiratory Illness (ARI) prior to 2 weeks (\<Day 15) after each vaccination (mES-RSV set). Only participants with data available at specified timepoints were included in analysis.
First episode of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated LRTD during the first season was assessed. The case definition for RSV-confirmed LRTD is as follows: Presence of at least one RSV-positive swab detected by RT-PCR.
Outcome measures
| Measure |
RSVPreF3 Group
n=12466 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12494 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine
|
7 Participants
|
40 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the Northern Hemisphere [NH] (assessed approximately over 2 and 3 years in NH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2 administration.
Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.
Outcome measures
| Measure |
RSVPreF3 Group
n=12469 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
Season 2 (NH)
|
30 Participants
|
139 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
Season 3 (NH)
|
48 Participants
|
215 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the NH (assessed approximately over 2 and 3 years in NH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2 administration.
Efficacy of annual revaccination doses of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.
Outcome measures
| Measure |
RSVPreF3 Group
n=12469 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following Annual Revaccination Doses of the RSVPreF3 OA Vaccine
Season 2 (NH)
|
30 Participants
|
139 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following Annual Revaccination Doses of the RSVPreF3 OA Vaccine
Season 3 (NH)
|
38 Participants
|
192 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2 administration.
Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
RT-PCR-confirmed RSV-A LRTD
|
14 Participants
|
80 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
RT-PCR-confirmed RSV-B LRTD
|
34 Participants
|
135 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose and 1 annual revaccination dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following 1 Annual Revaccination Dose
RT-PCR-confirmed RSV-A LRTD
|
17 Participants
|
65 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following 1 Annual Revaccination Dose
RT-PCR-confirmed RSV-B LRTD
|
21 Participants
|
127 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-vaccination up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis.
Outcome measures
| Measure |
RSVPreF3 Group
n=12469 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12503 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed LRTD Caused by Human Metapneumovirus (hMPV) up to the End of Season 1 Following a Single Dose of the RSVPreF3 OA Vaccine
|
53 Participants
|
65 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, in the following age categories: greater than or equal to (≥) 65 years of age (YOA), ≥70 YOA and ≥80 YOA.
Outcome measures
| Measure |
RSVPreF3 Group
n=9261 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=9328 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), >=65 YOA
|
38 Participants
|
156 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), >=70 YOA
|
20 Participants
|
98 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), >=80 YOA,
|
5 Participants
|
13 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), >=65 YOA
|
28 Participants
|
137 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), >=70 YOA
|
19 Participants
|
87 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), >=80 YOA
|
5 Participants
|
12 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first dose or start of the RSV season to the first occurrence of RSV-confirmed LRTD at each RSV season (assessed approximately over 7 months at each season [Seasons 1 and 2 in SH, Seasons 1, 2 and 3 in NH])Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. Analysis is presented based on the groups at each season (RSVPreF3 group for Season 1, RSV\_1\_dose and RSV\_annual groups for Seasons 2 and 3, Placebo group for Season 1, 2 and 3).
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by RSV season as follows: VE after each season includes the first occurrence of episodes reported from Day 15 post vaccination at first season, and for the next seasons, excluding analysis of participants who already reported a case in the previous season. The RSV season may be extended based on epidemiology data.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=4988 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
n=4968 Participants
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Season 1
|
7 Participants
|
36 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Season 2 (Single dose)
|
—
|
98 Participants
|
19 Participants
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Season 2 (Annual revaccination)
|
—
|
98 Participants
|
—
|
22 Participants
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Season 3 (Single dose)
|
—
|
60 Participants
|
16 Participants
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Season 3 (Annual revaccination)
|
—
|
37 Participants
|
—
|
6 Participants
|
SECONDARY outcome
Timeframe: From Day 15 post first dose and each revaccination dose up to next dose or end of study (assessed approximately over a year after each vaccination [at Year 1, Year 2 and Year 3])Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. Analysis is presented based on the groups at each season (RSVPreF3 group for Year 1, RSV\_1\_dose and RSV\_annual groups for Years 2 and 3, Placebo group for Years 1, 2 and 3).
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by years after vaccination as follows: VE at each year includes the first occurrence of episodes reported from Day 14 post vaccination at first year, and for the next years, excluding analysis of participants who already reported a case in the previous year.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=4988 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
n=4968 Participants
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Year 1
|
10 Participants
|
47 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Year 2 (Single dose)
|
—
|
106 Participants
|
22 Participants
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Year 2 (Annual revaccination)
|
—
|
106 Participants
|
—
|
22 Participants
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Year 3 (Single dose)
|
—
|
61 Participants
|
16 Participants
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD, Year 3 (Annual revaccination)
|
—
|
38 Participants
|
—
|
6 Participants
|
SECONDARY outcome
Timeframe: From Day 15 post first dose to the first occurrence of RSV LRTD (assessed approximately over 3 years in the NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Season 3 (NH) (Single dose)
|
48 Participants
|
215 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Season 3 (NH) (Annual revaccination)
|
38 Participants
|
192 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Season 1
|
10 Participants
|
47 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Season 2 (Single dose)
|
32 Participants
|
154 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Season 2 (Annual revaccination)
|
32 Participants
|
154 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities using Charlson Comorbidity Index. Low/medium Risk = Participants with co-morbidity score at baseline less than or equal to 3 (Charlson Index); High Risk = Participants with co-morbidity score at baseline greater than 3 (Charlson Index).
Outcome measures
| Measure |
RSVPreF3 Group
n=8126 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=8268 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), Low/Medium risk
|
24 Participants
|
119 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), High risk
|
24 Participants
|
96 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), Low/Medium risk
|
18 Participants
|
108 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), High risk
|
20 Participants
|
84 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities of interest divided into 2: cardiorespiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, any chronic respiratory or pulmonary disease, and endocrinometabolic conditions such as diabetes mellitus type 1 or 2, chronic heart failure and advanced liver or renal disease.
Outcome measures
| Measure |
RSVPreF3 Group
n=7454 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=7547 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Single dose), No pre-existing comorbidity of interest
|
23 Participants
|
99 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Single dose), At least 1 pre-existing comorbidity of interest
|
25 Participants
|
116 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Single dose), At least 1 pre-existing Cardiorespiratory condition
|
17 Participants
|
85 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Single dose), At least 1 pre-existing Endocrinometabolic condition
|
12 Participants
|
55 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Annual revaccination), No pre-existing comorbidity of interest
|
20 Participants
|
91 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing comorbidity of interest
|
18 Participants
|
101 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing Cardiorespiratory condition
|
11 Participants
|
73 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing Endocrinometabolic condition
|
9 Participants
|
49 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and /or B associated LRTD episode according to the case definition, by baseline frailty status of frail, pre-frail and fit. Frail = Participants with a walking speed of less than (\<) 0.4 meters per second (m/s) or who were not able to perform the test; Pre-Frail = Participants with a walking speed between 0.4-0.99 m/s; Fit = Participants with a walking speed of ≥1 m/s.
Outcome measures
| Measure |
RSVPreF3 Group
n=7464 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=7523 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), Frail
|
2 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), Pre-Frail
|
12 Participants
|
67 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Single dose), Fit
|
34 Participants
|
145 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), Frail
|
1 Participants
|
1 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), Pre-Frail
|
10 Participants
|
63 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV LRTD (Annual revaccination), Fit
|
27 Participants
|
126 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated severe LRTD episode. Case definition for RSV-confirmed severe LRTD: An RT-PCR confirmed case of RSV-associated severe LRTD is characterized by presence of lower respiratory signs or an LRTD episode assessed as severe by the investigator (Severe LRTD case definition 1) or presence of an LRTD with need for oxygen supplementation or need for positive airway pressure therapy or need for other types of mechanical ventilation (Severe LRTD case definition 2) and with at least one RSV positive swab detected by RT-PCR.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV severe LRTD (Single dose), Any
|
15 Participants
|
75 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV severe LRTD (Single dose), Definition 1: Clinical symptomology
|
15 Participants
|
75 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV severe LRTD (Single dose), Definition 2: Supportive therapy
|
2 Participants
|
7 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Any
|
9 Participants
|
67 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Definition 1: Clinical symptomology
|
9 Participants
|
67 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Definition 2: Supportive therapy
|
0 Participants
|
6 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV confirmed A and/or B associated ARI episode. A case of RT-PCR confirmed RSV-associated ARI is characterized by the presence of respiratory symptoms/signs for at least 24 hours OR respiratory symptom/sign + systemic symptom/sign for at least 24 hours with at least one RSV-positive swab detected by RT-PCR.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV ARI (Single dose)
|
131 Participants
|
428 Participants
|
—
|
—
|
|
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
RT-PCR-confirmed RSV ARI (Annual revaccination)
|
103 Participants
|
385 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against any ARI and any LRTD.
Outcome measures
| Measure |
RSVPreF3 Group
n=12469 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12503 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Any ARI (Single dose)
|
4858 Participants
|
6096 Participants
|
—
|
—
|
|
Number of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Any ARI (Annual revaccination)
|
4731 Participants
|
5914 Participants
|
—
|
—
|
|
Number of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Any LRTD (Single dose)
|
12450 Participants
|
3352 Participants
|
—
|
—
|
|
Number of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Any LRTD (Annual revaccination)
|
2308 Participants
|
3210 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
RSV infection was confirmed by RT-PCR.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease (Single dose), during season
|
2 Participants
|
4 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease or related complication (Single dose), during season
|
2 Participants
|
4 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease (Annual revaccination),during season
|
0 Participants
|
4 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease or related complication (Annual revaccination), during season
|
0 Participants
|
4 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease (Single dose), up to end of study
|
2 Participants
|
6 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease or related complication (Single dose), up to end of study
|
2 Participants
|
6 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease (Annual revaccination), up to end of study
|
0 Participants
|
6 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV respiratory disease or related complication (Annual revaccination), up to end of study
|
0 Participants
|
6 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system.
Outcome measures
| Measure |
RSVPreF3 Group
n=12469 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12503 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease (Single dose), during seasons
|
121 Participants
|
174 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease or related complication (Single dose), during seasons
|
131 Participants
|
180 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease (Annual revaccination), during seasons
|
114 Participants
|
163 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease or related complication (Annual revaccination), during seasons
|
119 Participants
|
169 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease (Single dose), up to end of study
|
167 Participants
|
221 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease or related complication (Single dose), up to end of study
|
179 Participants
|
230 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease (Annual revaccination), up to end of study
|
163 Participants
|
208 Participants
|
—
|
—
|
|
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Any respiratory disease or related complication (Annual revaccination), up to end of study
|
171 Participants
|
217 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
RSV infection was confirmed by RT-PCR.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Related to RT-PCR-confirmed RSV ARI (Single dose), up to end of study
|
12 Participants
|
50 Participants
|
—
|
—
|
|
Number of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Related to RT-PCR-confirmed RSV ARI (Annual revaccination), up to end of study
|
11 Participants
|
46 Participants
|
—
|
—
|
|
Number of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Related to RT-PCR-confirmed RSV ARI (Single dose), during season
|
9 Participants
|
43 Participants
|
—
|
—
|
|
Number of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Related to RT-PCR-confirmed RSV ARI (Annual revaccination), during season
|
9 Participants
|
39 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
RSV infection was confirmed by RT-PCR.
Outcome measures
| Measure |
RSVPreF3 Group
n=12469 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12503 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Complications related to any ARI (Single dose), during season
|
438 Participants
|
695 Participants
|
—
|
—
|
|
Number of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Complications related to any ARI (Annual revaccination), during season
|
417 Participants
|
660 Participants
|
—
|
—
|
|
Number of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Complications related to any ARI (Single dose), up to end of study
|
620 Participants
|
863 Participants
|
—
|
—
|
|
Number of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
Complications related to any ARI (Annual revaccination), up to end of study
|
579 Participants
|
823 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
For this outcome measure, the Health Related -Quality of life (HR-QOL) score is measured by Flu-PRO questionnaire version 2.0. The Flu-PRO is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The objective of this outcome measure was to present data only for chest/respiratory system after a single dose and after annual revaccination. The FLU-PRO score was computed as the mean score across questionaire items for chest/respiratory body system, with the scores ranging from 0 (symptom free) to 4 (very severe symptoms).
Outcome measures
| Measure |
RSVPreF3 Group
n=121 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=377 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Maximum Influenza Patient-Reported Outcome (Flu-PRO) Chest Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Chest / Respiratory (Single dose)
|
1.60 Scores on a scale
Standard Deviation 0.89
|
1.97 Scores on a scale
Standard Deviation 0.88
|
—
|
—
|
|
Maximum Influenza Patient-Reported Outcome (Flu-PRO) Chest Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Chest / Respiratory (Annual revaccination)
|
1.50 Scores on a scale
Standard Deviation 0.87
|
1.96 Scores on a scale
Standard Deviation 0.89
|
—
|
—
|
SECONDARY outcome
Timeframe: During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
The Flu-PRO questionnaire version 2.0 is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The FLU-PRO total score was computed as the mean score across all 32 items of the questionaire for all 6 body systems, with the total scores ranging from 0 (symptom free) to 4 (very severe symptoms).
Outcome measures
| Measure |
RSVPreF3 Group
n=131 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=428 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Least Square Mean Flu-PRO Total Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Day 1 to Day 7 (Single dose)
|
0.85 Scores on a scale
Standard Error 0.07
|
0.92 Scores on a scale
Standard Error 0.06
|
—
|
—
|
|
Least Square Mean Flu-PRO Total Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Day 1 to Day 7 (Annual revaccination)
|
0.81 Scores on a scale
Standard Error 0.07
|
0.90 Scores on a scale
Standard Error 0.06
|
—
|
—
|
SECONDARY outcome
Timeframe: At the ARI visit (assessed from Day 15 post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
The EQ-5D is a general health utility questionnaire with health states, defined through 5 dimensions- mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. A participant who responds 1 (no problem/no symptom) to all 5 items has a profile "11111" and similarly a participant who responds 3 (the highest level of difficulty or symptom) to all items has a profile "33333". The health states indicated in these 5 dimensions are converted and presented as a single mean index value as recommended by EuroQol group, where values range from 0 (worst) to 1 (full health).
Outcome measures
| Measure |
RSVPreF3 Group
n=106 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=362 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
EuroQol 5-dimension Health Questionnaire (EQ-5D) Utility Score for Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
At ARI visit (Single dose)
|
0.8164 Scores on a scale
Standard Error 0.0258
|
0.7886 Scores on a scale
Standard Error 0.0197
|
—
|
—
|
|
EuroQol 5-dimension Health Questionnaire (EQ-5D) Utility Score for Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
At ARI visit (Annual revaccination)
|
0.8377 Scores on a scale
Standard Error 0.0259
|
0.7966 Scores on a scale
Standard Error 0.0197
|
—
|
—
|
SECONDARY outcome
Timeframe: At the ARI visit (assessed from one-month post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
SF-12 is a health survey with 12 questions, covering 8 domains- physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Summary scores are computed from these domains for the physical and mental component. The total score of the SF-12 questionnaire is evaluated on a scale from 0 to 100, with a higher score indicating a better perceived health-related quality of life.
Outcome measures
| Measure |
RSVPreF3 Group
n=105 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=361 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Least Square Mean of Short Form-12 (SF-12) Health Survey for Participants With RT-PCR Confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
At ARI visit (Single dose)
|
59.43 Scores on a scale
Standard Error 4.07
|
57.51 Scores on a scale
Standard Error 3.15
|
—
|
—
|
|
Least Square Mean of Short Form-12 (SF-12) Health Survey for Participants With RT-PCR Confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
At ARI visit (Annual revaccination)
|
63.65 Scores on a scale
Standard Error 4.15
|
59.02 Scores on a scale
Standard Error 3.18
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post first dose to end of Season 1, from 15 days post-second dose administration to end of Season 2, and from start to end of Season 3 [all seasons summing approximately 3 years in NH and 2.5-3 years in SH]Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis.
The duration in days of RT-PCR confirmed RSV A and/or B ARI and LRTD episodes are described.
Outcome measures
| Measure |
RSVPreF3 Group
n=40 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=208 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=61 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
n=45 Participants
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
RT-PCR-confirmed RSV ARI, Season 1
|
12.0 Days
Interval 8.0 to 19.0
|
15.0 Days
Interval 11.0 to 22.0
|
—
|
—
|
|
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
RT-PCR-confirmed RSV LRTD, Season 1
|
15.5 Days
Interval 8.0 to 19.0
|
20.0 Days
Interval 15.0 to 27.0
|
—
|
—
|
|
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
RT-PCR-confirmed RSV ARI, Season 2
|
—
|
16.0 Days
Interval 12.0 to 24.0
|
14.0 Days
Interval 10.0 to 23.0
|
13.0 Days
Interval 9.0 to 18.0
|
|
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
RT-PCR-confirmed RSV LRTD, Season 2
|
—
|
16.0 Days
Interval 13.0 to 24.0
|
17.0 Days
Interval 10.0 to 28.0
|
14.0 Days
Interval 9.0 to 23.0
|
|
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
RT-PCR-confirmed RSV ARI, Season 3
|
—
|
16.0 Days
Interval 14.0 to 22.0
|
16.0 Days
Interval 13.0 to 24.0
|
10.0 Days
Interval 7.0 to 21.0
|
|
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
RT-PCR-confirmed RSV LRTD, Season 3
|
—
|
17.5 Days
Interval 14.5 to 26.0
|
16.5 Days
Interval 15.0 to 24.5
|
12.0 Days
Interval 7.0 to 21.0
|
SECONDARY outcome
Timeframe: From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]Population: Analysis was performed on the mES. Only participants with data available for symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes at specified timepoints were included in analysis.
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
Outcome measures
| Measure |
RSVPreF3 Group
n=40 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=110 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Nasal Congestion
|
28 Participants
|
83 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Rhinorrhea
|
32 Participants
|
93 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Sore Throat
|
26 Participants
|
76 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Cough (new or increased)
|
36 Participants
|
101 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Sputum (new or increased)
|
20 Participants
|
75 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Shortness of breath or dyspnea (new or increased)
|
7 Participants
|
35 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Wheezing (new or increased)
|
5 Participants
|
25 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Crackles
|
1 Participants
|
6 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Rhonchi
|
1 Participants
|
13 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Respiratory rate ≥20 breaths/minute
|
3 Participants
|
11 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Low or decreased oxygen saturation
|
1 Participants
|
9 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Fever
|
2 Participants
|
8 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Feverishness
|
8 Participants
|
24 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Fatigue
|
22 Participants
|
67 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Body aches
|
12 Participants
|
40 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Headache
|
20 Participants
|
55 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Decreased appetite
|
13 Participants
|
42 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Need for oxygen supplementation
|
0 Participants
|
4 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Need for positive airway pressure therapy
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Need of other types of mechanical ventilation
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
Other symptoms or signs
|
7 Participants
|
22 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])Population: Analysis was performed on the modified Exposed set for Dose 2 (mES-Dose 2), which included all participants who received the first and second doses of the study intervention, and who did not report an RSV-confirmed ARI prior to Day 15 after each vaccination. Only participants with data available for symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes at specified timepoints were included in analysis.
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
Outcome measures
| Measure |
RSVPreF3 Group
n=208 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=61 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=45 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Nasal Congestion
|
162 Participants
|
43 Participants
|
31 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Rhinorrhea
|
186 Participants
|
52 Participants
|
39 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Sore Throat
|
147 Participants
|
43 Participants
|
33 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Cough (new or increased)
|
201 Participants
|
55 Participants
|
41 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Sputum (new or increased)
|
150 Participants
|
39 Participants
|
29 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Shortness of breath or dyspnea (new or increased)
|
79 Participants
|
17 Participants
|
19 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Wheezing (new or increased)
|
56 Participants
|
15 Participants
|
10 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Crackles
|
19 Participants
|
2 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Rhonchi
|
32 Participants
|
8 Participants
|
7 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Respiratory rate ≥20 breaths/minute
|
21 Participants
|
5 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Low or decreased oxygen saturation
|
8 Participants
|
1 Participants
|
4 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Fever
|
21 Participants
|
5 Participants
|
7 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Feverishness
|
64 Participants
|
13 Participants
|
15 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Fatigue
|
145 Participants
|
34 Participants
|
33 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Body aches
|
91 Participants
|
27 Participants
|
24 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Headache
|
124 Participants
|
36 Participants
|
28 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Decreased appetite
|
85 Participants
|
20 Participants
|
18 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Need for oxygen supplementation
|
1 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Need for positive airway pressure therapy
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Need of other types of mechanical ventilation
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
Other symptoms or signs
|
48 Participants
|
12 Participants
|
14 Participants
|
—
|
SECONDARY outcome
Timeframe: From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)Population: Analysis was performed on the mES-Dose 2. Only participants with data available for symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes at specified timepoints were included in analysis. Only participants in NH were included in this analysis.
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
Outcome measures
| Measure |
RSVPreF3 Group
n=113 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=30 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=19 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Nasal Congestion
|
101 Participants
|
25 Participants
|
15 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Rhinorrhea
|
98 Participants
|
26 Participants
|
17 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Sore Throat
|
76 Participants
|
17 Participants
|
14 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Cough (new or increased)
|
111 Participants
|
27 Participants
|
18 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Sputum (new or increased)
|
86 Participants
|
23 Participants
|
10 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Shortness of breath or dyspnea (new or increased)
|
42 Participants
|
10 Participants
|
5 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Wheezing (new or increased)
|
32 Participants
|
6 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Crackles
|
10 Participants
|
2 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Rhonchi
|
16 Participants
|
8 Participants
|
2 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Respiratory rate ≥20 breaths/minute
|
9 Participants
|
3 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Low or decreased oxygen saturation
|
11 Participants
|
1 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Fever
|
10 Participants
|
2 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Feverishness
|
32 Participants
|
14 Participants
|
6 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Fatigue
|
85 Participants
|
21 Participants
|
15 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Body aches
|
56 Participants
|
16 Participants
|
10 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Headache
|
66 Participants
|
16 Participants
|
12 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Decreased appetite
|
52 Participants
|
13 Participants
|
12 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Need for oxygen supplementation
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Need for positive airway pressure therapy
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Need of other types of mechanical ventilation
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
Other symptoms or signs
|
35 Participants
|
6 Participants
|
9 Participants
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]Population: Analysis was performed on the mES-RSV. Only participants with data available for symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes at specified timepoints were included in analysis.
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
Outcome measures
| Measure |
RSVPreF3 Group
n=10 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=47 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Nasal Congestion
|
7 Participants
|
38 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Rhinorrhea
|
9 Participants
|
38 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Sore Throat
|
5 Participants
|
33 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Cough (new or increased)
|
10 Participants
|
47 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Sputum (new or increased)
|
8 Participants
|
36 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Shortness of breath or dyspnea (new or increased)
|
4 Participants
|
29 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Wheezing (new or increased)
|
5 Participants
|
24 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Crackles
|
1 Participants
|
6 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Rhonchi
|
0 Participants
|
13 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Respiratory rate ≥20 breaths/minute
|
3 Participants
|
10 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Low or decreased oxygen saturation
|
1 Participants
|
8 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Fever
|
1 Participants
|
8 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Feverishness
|
2 Participants
|
16 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Fatigue
|
6 Participants
|
37 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Body aches
|
5 Participants
|
22 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Headache
|
4 Participants
|
27 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Decreased appetite
|
7 Participants
|
26 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Need for oxygen supplementation
|
0 Participants
|
4 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Need for positive airway pressure therapy
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Need of other types of mechanical ventilation
|
0 Participants
|
0 Participants
|
—
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
Other symptoms or signs
|
2 Participants
|
12 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])Population: Analysis was performed on the mES-Dose 2. Only participants with data available for symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes at specified timepoints were included in analysis.
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
Outcome measures
| Measure |
RSVPreF3 Group
n=107 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=22 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=22 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Nasal Congestion
|
90 Participants
|
20 Participants
|
15 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Rhinorrhea
|
96 Participants
|
20 Participants
|
19 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Sore Throat
|
79 Participants
|
17 Participants
|
15 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Cough (new or increased)
|
106 Participants
|
21 Participants
|
20 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Sputum (new or increased)
|
95 Participants
|
19 Participants
|
17 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Shortness of breath or dyspnea (new or increased)
|
72 Participants
|
14 Participants
|
13 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Wheezing (new or increased)
|
56 Participants
|
15 Participants
|
10 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Crackles
|
19 Participants
|
2 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Rhonchi
|
31 Participants
|
5 Participants
|
7 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Respiratory rate ≥20 breaths/minute
|
21 Participants
|
5 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Low or decreased oxygen saturation
|
8 Participants
|
1 Participants
|
4 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Fever
|
13 Participants
|
3 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Feverishness
|
44 Participants
|
7 Participants
|
8 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Fatigue
|
86 Participants
|
16 Participants
|
15 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Body aches
|
53 Participants
|
15 Participants
|
11 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Headache
|
70 Participants
|
17 Participants
|
14 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Decreased appetite
|
47 Participants
|
13 Participants
|
11 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Need for oxygen supplementation
|
1 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Need for positive airway pressure therapy
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Need of other types of mechanical ventilation
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
Other symptoms or signs
|
28 Participants
|
3 Participants
|
5 Participants
|
—
|
SECONDARY outcome
Timeframe: From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)Population: Analysis was performed on the mES-Dose 2. Only participants with data available for symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes at specified timepoints were included in analysis. Only participants in NH were included in this analysis.
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
Outcome measures
| Measure |
RSVPreF3 Group
n=61 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=16 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=6 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Nasal Congestion
|
54 Participants
|
13 Participants
|
4 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Rhinorrhea
|
50 Participants
|
14 Participants
|
4 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Sore Throat
|
42 Participants
|
9 Participants
|
5 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Cough (new or increased)
|
60 Participants
|
15 Participants
|
6 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Sputum (new or increased)
|
53 Participants
|
14 Participants
|
5 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Shortness of breath or dyspnea (new or increased)
|
38 Participants
|
9 Participants
|
4 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Wheezing (new or increased)
|
32 Participants
|
5 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Crackles
|
10 Participants
|
2 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Rhonchi
|
16 Participants
|
8 Participants
|
2 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Respiratory rate ≥20 breaths/minute
|
9 Participants
|
3 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Low or decreased oxygen saturation
|
11 Participants
|
1 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Fever
|
6 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Feverishness
|
22 Participants
|
8 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Fatigue
|
49 Participants
|
13 Participants
|
6 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Body aches
|
39 Participants
|
10 Participants
|
5 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Headache
|
41 Participants
|
10 Participants
|
5 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Decreased appetite
|
33 Participants
|
11 Participants
|
3 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Need for oxygen supplementation
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Need for positive airway pressure therapy
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Need of other types of mechanical ventilation
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
Other symptoms or signs
|
22 Participants
|
4 Participants
|
3 Participants
|
—
|
SECONDARY outcome
Timeframe: Assessed during the study period (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the mES-RSV. Only participants with data available at specified timepoints were included in analysis. For single dose evaluation, participants from the RSV\_annual group who received RSVPreF3 OA investigational vaccine at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2. For annual dose evaluation, participants from the RSV\_1\_dose group who received Placebo at Dose 2 contributed to Season 1 data only and were censored starting from Dose 2.
RSV A and/or B ARI and LRTD episodes were assessed as "mild", "moderate" or "severe" by the investigator after the single dose and after annual revaccination. Mild = an ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate = an ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe = an ARI/LRTD episode which prevents normal, everyday activities.
Outcome measures
| Measure |
RSVPreF3 Group
n=12468 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=12498 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
Mild (Single dose)
|
16 Participants
|
49 Participants
|
—
|
—
|
|
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
Moderate (Single dose)
|
29 Participants
|
138 Participants
|
—
|
—
|
|
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
Severe (Single dose)
|
3 Participants
|
28 Participants
|
—
|
—
|
|
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
Mild (Annual revaccination)
|
15 Participants
|
48 Participants
|
—
|
—
|
|
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
Moderate (Annual revaccination)
|
23 Participants
|
120 Participants
|
—
|
—
|
|
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
Severe (Annual revaccination)
|
0 Participants
|
24 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)Population: Analysis was performed in a subset of participants from the Per Protocol Set for immunogenicity (PPSi), which included participants who received at least the first dose of the study intervention, have post-vaccination immunogenicity data available, and did not meet protocol deviations that lead to exclusion. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
The RSVPreF3 IgG antibody concentrations are expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL).
Outcome measures
| Measure |
RSVPreF3 Group
n=878 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=441 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=431 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
RSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations
Pre-dose 1 at day 1
|
7090.2 EU/mL
Interval 6783.4 to 7410.9
|
6956.5 EU/mL
Interval 6505.2 to 7439.2
|
7101.1 EU/mL
Interval 6640.7 to 7593.4
|
—
|
|
RSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations
Post-dose 1 at day 31
|
7053.2 EU/mL
Interval 6732.0 to 7389.8
|
89361.9 EU/mL
Interval 83409.6 to 95738.9
|
93769.5 EU/mL
Interval 87896.6 to 100034.8
|
—
|
|
RSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations
Pre-Season 2
|
7594.8 EU/mL
Interval 7203.9 to 8007.0
|
24103.6 EU/mL
Interval 22366.8 to 25975.3
|
24523.8 EU/mL
Interval 22748.7 to 26437.4
|
—
|
|
RSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations
Pre-Season 3
|
8436.6 EU/mL
Interval 7927.3 to 8978.7
|
21255.0 EU/mL
Interval 19587.7 to 23064.2
|
28925.3 EU/mL
Interval 26928.0 to 31070.7
|
—
|
SECONDARY outcome
Timeframe: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)Population: Analysis was performed in a subset of participants from the PPSi. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
The RSV A neutralizing antibody titers are expressed as geometric mean titers (GMTs).
Outcome measures
| Measure |
RSVPreF3 Group
n=878 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=441 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=431 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
RSV A Neutralizing Antibody Titers
Pre-dose 1 at day 1
|
933.5 Titers
Interval 881.8 to 988.4
|
899.8 Titers
Interval 829.1 to 976.5
|
929.3 Titers
Interval 852.6 to 1013.0
|
—
|
|
RSV A Neutralizing Antibody Titers
Post-dose 1 at day 31
|
880.8 Titers
Interval 828.9 to 935.9
|
8915.5 Titers
Interval 8080.6 to 9836.8
|
9652.4 Titers
Interval 8727.5 to 10675.3
|
—
|
|
RSV A Neutralizing Antibody Titers
Pre-Season 2
|
865.8 Titers
Interval 809.6 to 925.9
|
2535.9 Titers
Interval 2284.7 to 2814.8
|
2918.4 Titers
Interval 2594.5 to 3282.9
|
—
|
|
RSV A Neutralizing Antibody Titers
Pre-Season 3
|
977.9 Titers
Interval 905.5 to 1056.0
|
2049.7 Titers
Interval 1841.0 to 2282.1
|
2996.1 Titers
Interval 2665.3 to 3368.1
|
—
|
SECONDARY outcome
Timeframe: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)Population: Analysis was performed on PPSi. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
RSV B neutralizing antibodies are expressed as GMTs.
Outcome measures
| Measure |
RSVPreF3 Group
n=878 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=441 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=431 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
RSV B Neutralizing Antibody Titers
Pre-dose 1 at day 1
|
1249.7 Titers
Interval 1179.1 to 1324.5
|
1189.9 Titers
Interval 1097.4 to 1290.2
|
1187.2 Titers
Interval 1096.7 to 1285.2
|
—
|
|
RSV B Neutralizing Antibody Titers
Post-dose 1 at day 31
|
1262.4 Titers
Interval 1183.8 to 1346.2
|
9928.9 Titers
Interval 9103.7 to 10829.0
|
10253.4 Titers
Interval 9362.7 to 11228.9
|
—
|
|
RSV B Neutralizing Antibody Titers
Pre-Season 2
|
1229.7 Titers
Interval 1149.9 to 1315.1
|
2955.5 Titers
Interval 2677.0 to 3262.9
|
2979.2 Titers
Interval 2692.2 to 3296.9
|
—
|
|
RSV B Neutralizing Antibody Titers
Pre-Season 3
|
946.8 Titers
Interval 873.5 to 1026.3
|
2054.5 Titers
Interval 1829.9 to 2306.5
|
2515.3 Titers
Interval 2249.9 to 2812.0
|
—
|
SECONDARY outcome
Timeframe: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])Population: Analysis was performed on a subset of participants from the solicited safety set (SSS), which included participants who received at least the first dose of the study intervention and with the solicited administration site events diary card data available after the corresponding vaccination for the specified duration. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed administration site events include pain, erythema and swelling.
Outcome measures
| Measure |
RSVPreF3 Group
n=874 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=442 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=437 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Erythema, Dose 1, Any
|
10 Participants
|
41 Participants
|
30 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Erythema, Dose 1, Grade 3
|
0 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Erythema, Dose 2, Any
|
1 Participants
|
1 Participants
|
31 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Erythema , Dose 2, Grade 3
|
0 Participants
|
0 Participants
|
3 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Erythema, Dose 3 (NH), Any
|
0 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Erythema, Dose 3 (NH), Grade 3
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Pain, Dose 1, Any
|
81 Participants
|
267 Participants
|
268 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Pain, Dose 1, Grade 3
|
0 Participants
|
6 Participants
|
3 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Pain, Dose 2, Any
|
51 Participants
|
30 Participants
|
169 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Pain, Dose 2, Grade 3
|
0 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Pain, Dose 3 (NH), Any
|
7 Participants
|
3 Participants
|
25 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Pain, Dose 3 (NH), Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Swelling, Dose 1, Any
|
7 Participants
|
25 Participants
|
28 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Swelling, Dose 1, Grade 3
|
0 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Swelling, Dose 2, Any
|
2 Participants
|
0 Participants
|
23 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Swelling, Dose 2, Grade 3
|
0 Participants
|
0 Participants
|
6 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Swelling, Dose 3 (NH), Any
|
0 Participants
|
1 Participants
|
2 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Swelling, Dose 3 (NH), Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])Population: Analysis was performed on a subset of participants from the solicited safety set (SSS), which included participants who received at least the first dose of the study intervention and with the solicited systemic events diary card data available after the corresponding vaccination for the specified duration. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed solicited systemic events include arthralgia, fatigue, fever, headache and myalgia. Fever is defined as a temperature ≥ 38.0°C by any route. Grade 3 fever is defined as temperature \>39°C by any route.
Outcome measures
| Measure |
RSVPreF3 Group
n=878 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=442 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=437 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Arthralgia, Dose 1, Any
|
56 Participants
|
74 Participants
|
84 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Arthralgia, Dose 1, Grade 3
|
5 Participants
|
5 Participants
|
6 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Arthralgia, Dose 2, Any
|
48 Participants
|
20 Participants
|
55 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Arthralgia, Dose 2, Grade 3
|
2 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Arthralgia, Dose 3 (NH), Any
|
5 Participants
|
2 Participants
|
5 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Arthralgia, Dose 3 (NH), Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fatigue, Dose 1, Any
|
141 Participants
|
143 Participants
|
153 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fatigue, Dose 1, Grade 3
|
4 Participants
|
6 Participants
|
9 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fatigue, Dose 2, Any
|
80 Participants
|
44 Participants
|
98 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fatigue, Dose 2, Grade 3
|
7 Participants
|
2 Participants
|
3 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fatigue, Dose 3 (NH), Any
|
12 Participants
|
8 Participants
|
9 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fatigue, Dose 3 (NH), Grade 3
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fever, Dose 1, Any
|
3 Participants
|
14 Participants
|
4 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fever, Dose 1, Grade 3
|
1 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fever, Dose 2, Any
|
4 Participants
|
1 Participants
|
6 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fever, Dose 2, Grade 3
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fever, Dose 3 (NH), Any
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Fever, Dose 3 (NH), Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Headache, Dose 1, Any
|
111 Participants
|
116 Participants
|
123 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Headache, Dose 1, Grade 3
|
0 Participants
|
6 Participants
|
5 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Headache, Dose 2, Any
|
60 Participants
|
41 Participants
|
73 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Headache, Dose 2, Grade 3
|
4 Participants
|
1 Participants
|
2 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Headache, Dose 3 (NH), Any
|
9 Participants
|
6 Participants
|
5 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Headache, Dose 3 (NH), Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Myalgia, Dose 1, Any
|
72 Participants
|
127 Participants
|
128 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Myalgia, Dose 1, Grade 3
|
3 Participants
|
5 Participants
|
7 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Myalgia, Dose 2, Any
|
52 Participants
|
20 Participants
|
82 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Myalgia, Dose 2, Grade 3
|
3 Participants
|
0 Participants
|
3 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Myalgia, Dose 3 (NH), Any
|
5 Participants
|
3 Participants
|
7 Participants
|
—
|
|
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Myalgia, Dose 3 (NH), Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])Population: Analysis was performed on a subset of participants from the solicited safety set (SSS), which included participants who received at least the first dose of the study intervention and with the solicited administration site events diary card data available after the corresponding vaccination for the specified duration. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
Outcome measures
| Measure |
RSVPreF3 Group
n=81 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=267 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=268 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Days With Solicited Administration Site Adverse Events
Erythema, Dose 1
|
4.0 Days
Interval 2.0 to 4.0
|
3.0 Days
Interval 2.0 to 4.0
|
3.0 Days
Interval 2.0 to 4.0
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Erythema, Dose 2
|
4.0 Days
Interval 4.0 to 4.0
|
2.0 Days
Interval 2.0 to 2.0
|
3.0 Days
Interval 2.0 to 3.0
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Erythema, Dose 3 (NH)
|
—
|
—
|
3.0 Days
Interval 2.0 to 4.0
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Pain, Dose 1
|
1.0 Days
Interval 1.0 to 2.0
|
2.0 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 2.0 to 3.0
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Pain, Dose 2
|
1.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 2.0
|
2.0 Days
Interval 2.0 to 3.0
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Pain, Dose 3 (NH)
|
2.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 2.0
|
2.0 Days
Interval 1.0 to 2.0
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Swelling, Dose 1
|
4.0 Days
Interval 2.0 to 8.0
|
3.0 Days
Interval 2.0 to 4.0
|
3.0 Days
Interval 2.0 to 4.5
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Swelling, Dose 2
|
2.0 Days
Interval 1.0 to 3.0
|
—
|
3.0 Days
Interval 2.0 to 4.0
|
—
|
|
Number of Days With Solicited Administration Site Adverse Events
Swelling, Dose 3 (NH)
|
—
|
49.0 Days
Interval 49.0 to 49.0
|
1.5 Days
Interval 1.0 to 2.0
|
—
|
SECONDARY outcome
Timeframe: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])Population: Analysis was performed on a subset of participants from the solicited safety set (SSS), which included participants who received at least the first dose of the study intervention and with the solicited systemic events diary card data available after the corresponding vaccination for the specified duration. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
Outcome measures
| Measure |
RSVPreF3 Group
n=141 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=143 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=153 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Days With Solicited Systemic Adverse Events
Arthralgia, Dose 1
|
2.5 Days
Interval 1.0 to 4.0
|
2.0 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 1.0 to 3.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Arthralgia, Dose 2
|
2.0 Days
Interval 1.0 to 4.0
|
2.0 Days
Interval 1.0 to 3.0
|
1.0 Days
Interval 1.0 to 3.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Arthralgia, Dose 3 (NH)
|
4.0 Days
Interval 3.0 to 4.0
|
2.0 Days
Interval 1.0 to 3.0
|
4.0 Days
Interval 1.0 to 4.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Fatigue, Dose 1
|
1.0 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 1.0 to 3.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Fatigue, Dose 2
|
2.0 Days
Interval 1.0 to 4.0
|
1.5 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 1.0 to 3.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Fatigue, Dose 3 (NH)
|
1.0 Days
Interval 1.0 to 2.0
|
2.5 Days
Interval 1.0 to 3.5
|
2.0 Days
Interval 1.0 to 2.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Fever, Dose 1
|
1.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 1.0
|
1.0 Days
Interval 1.0 to 1.5
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Fever, Dose 2
|
2.0 Days
Interval 1.5 to 3.0
|
1.0 Days
Interval 1.0 to 1.0
|
1.0 Days
Interval 1.0 to 4.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Fever, Dose 3 (NH)
|
1.0 Days
Interval 1.0 to 1.0
|
—
|
—
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Headache, Dose 1
|
1.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 2.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Headache, Dose 2
|
2.0 Days
Interval 1.0 to 4.0
|
1.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 2.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Headache, Dose 3 (NH)
|
1.0 Days
Interval 1.0 to 2.0
|
1.0 Days
Interval 1.0 to 1.0
|
2.0 Days
Interval 2.0 to 2.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Myalgia, Dose 1
|
1.5 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 1.0 to 3.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Myalgia, Dose 2
|
2.0 Days
Interval 1.0 to 4.0
|
1.5 Days
Interval 1.0 to 2.0
|
2.0 Days
Interval 1.0 to 3.0
|
—
|
|
Number of Days With Solicited Systemic Adverse Events
Myalgia, Dose 3 (NH)
|
2.0 Days
Interval 1.0 to 3.0
|
3.0 Days
Interval 1.0 to 3.0
|
2.0 Days
Interval 1.0 to 4.0
|
—
|
SECONDARY outcome
Timeframe: During the 30-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH)Population: Analysis is performed on the Exposed Set, which included all participants that received at least the first vaccination. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside of the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Any= occurrence of the event regardless of intensity grade or relation to the study vaccination.
Outcome measures
| Measure |
RSVPreF3 Group
n=12503 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=6226 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=6243 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Any Unsolicited AEs
Any unsolicited AE (post Dose 1)
|
2334 Participants
|
2149 Participants
|
2136 Participants
|
—
|
|
Number of Participants With Any Unsolicited AEs
Any unsolicited AE (post Dose 2)
|
1570 Participants
|
824 Participants
|
1456 Participants
|
—
|
|
Number of Participants With Any Unsolicited AEs
Any unsolicited AE (post Dose 3)
|
422 Participants
|
233 Participants
|
397 Participants
|
—
|
SECONDARY outcome
Timeframe: From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])Population: Analysis is performed on the Exposed Set, which included all participants that received at least the first vaccination. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or in other situations that were considered serious per medical or scientific judgment. Any = occurrence of any SAE regardless of intensity grade or relation to study vaccination.
Outcome measures
| Measure |
RSVPreF3 Group
n=12503 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=6226 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=6243 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Serious Adverse Events (SAEs)
Any SAE (post Dose 1)
|
541 Participants
|
280 Participants
|
268 Participants
|
—
|
|
Number of Participants With Serious Adverse Events (SAEs)
Any SAE (post Dose 2)
|
497 Participants
|
239 Participants
|
229 Participants
|
—
|
|
Number of Participants With Serious Adverse Events (SAEs)
Any SAE (post Dose 3)
|
179 Participants
|
75 Participants
|
73 Participants
|
—
|
SECONDARY outcome
Timeframe: From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])Population: Analysis is performed on the Exposed Set, which included all participants that received at least the first vaccination. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
pIMDs aredefined as a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any= occurrence of any pIMD regardless of intensity grade or relation to the study vaccination.
Outcome measures
| Measure |
RSVPreF3 Group
n=12503 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=6226 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=6243 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Potential Immune Mediated Diseases (pIMDs)
Any pIMDs (post Dose 1)
|
39 Participants
|
27 Participants
|
19 Participants
|
—
|
|
Number of Participants With Potential Immune Mediated Diseases (pIMDs)
Any pIMDs (post Dose 2)
|
39 Participants
|
19 Participants
|
14 Participants
|
—
|
|
Number of Participants With Potential Immune Mediated Diseases (pIMDs)
Any pIMDs (post Dose 3)
|
13 Participants
|
8 Participants
|
10 Participants
|
—
|
SECONDARY outcome
Timeframe: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the Exposed Set. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
Related SAEs that occur throughout the study are assessed. Related SAEs= Any SAE related to investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator.
Outcome measures
| Measure |
RSVPreF3 Group
n=12503 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=6226 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=6243 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Related SAEs
|
12 Participants
|
8 Participants
|
12 Participants
|
—
|
SECONDARY outcome
Timeframe: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the Exposed Set. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
Fatal SAEs that occur throughout the study are assessed. Fatal SAEs= Any SAEs leading to deaths.
Outcome measures
| Measure |
RSVPreF3 Group
n=12503 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=6226 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=6243 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Fatal SAEs
|
265 Participants
|
111 Participants
|
120 Participants
|
—
|
SECONDARY outcome
Timeframe: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)Population: Analysis was performed on the Exposed Set. Only participants with data available at specified timepoints were included in analysis. Analysis is presented dose-wise after first dose administration and annual revaccinations.
Related pIMD = pIMD assessed by the investigator as related to the study vaccination.
Outcome measures
| Measure |
RSVPreF3 Group
n=12503 Participants
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
|
Placebo Group
n=6226 Participants
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
|
RSV_1_dose Group
n=6243 Participants
Participants received a dose of placebo every subsequent year after the vaccination at Day 1 of the study.
|
RSV_annual Group
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year after the vaccination at Day 1 of the study.
|
|---|---|---|---|---|
|
Number of Participants With Related pIMDs
|
9 Participants
|
7 Participants
|
5 Participants
|
—
|
Adverse Events
Placebo Group
Serious events: 1660 serious events
Other events: 5837 other events
Deaths: 265 deaths
RSV_1_dose Group
Serious events: 799 serious events
Other events: 3663 other events
Deaths: 111 deaths
RSV_annual Group
Serious events: 796 serious events
Other events: 3826 other events
Deaths: 120 deaths
Serious adverse events
| Measure |
Placebo Group
n=12503 participants at risk
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year.
|
RSV_1_dose Group
n=6226 participants at risk
Participants received a dose of placebo every subsequent year.
|
RSV_annual Group
n=6243 participants at risk
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year
|
|---|---|---|---|
|
Gastrointestinal disorders
Haematemesis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Ileus paralytic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Impaired gastric emptying
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Incarcerated inguinal hernia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Intestinal haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Large intestinal stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Mallory-Weiss syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Mesenteric artery thrombosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oedematous pancreatitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophageal achalasia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophageal fistula
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophageal mucosal tear
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic failure
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Peptic ulcer haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Rectal prolapse
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Retroperitoneal haematoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Salivary gland calculus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Strangulated umbilical hernia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Subileus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Superior mesenteric artery syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Thrombosis mesenteric vessel
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Tooth impacted
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Volvulus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.30%
38/12503 • Number of events 53 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.39%
24/6226 • Number of events 28 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6243 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.25%
31/12503 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.08%
10/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.06%
8/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Obstructive sleep apnoea syndrome
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia
|
0.64%
80/12503 • Number of events 84 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.59%
37/6226 • Number of events 42 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.54%
34/6243 • Number of events 35 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
COVID-19
|
0.27%
34/12503 • Number of events 34 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6226 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.30%
19/6243 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.21%
26/12503 • Number of events 26 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sepsis
|
0.18%
22/12503 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Urinary tract infection
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cellulitis
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Diverticulitis
|
0.07%
9/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Urosepsis
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Appendicitis
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastroenteritis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bronchitis
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Septic shock
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Influenza
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Osteomyelitis
|
0.06%
7/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Kidney infection
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pyelonephritis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Localised infection
|
0.05%
6/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia aspiration
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cystitis
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Endocarditis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Erysipelas
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia bacterial
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pyelonephritis acute
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Wound infection
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Arthritis bacterial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Escherichia sepsis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infection
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Post procedural infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Arthritis infective
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cholecystitis infective
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Device related infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Postoperative wound infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Atypical pneumonia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Clostridium difficile infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Diabetic foot infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Epididymitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Liver abscess
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Peritonitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory tract infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Staphylococcal infection
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Abdominal sepsis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Abscess limb
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Anal abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Appendicitis perforated
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Atypical mycobacterial infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bursitis infective
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Colonic abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Diverticulitis intestinal perforated
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Empyema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Escherichia bacteraemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gangrene
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastroenteritis norovirus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Groin abscess
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Intervertebral discitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Large intestine infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Neutropenic sepsis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Nosocomial infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia respiratory syncytial viral
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia viral
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Psoas abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pulmonary tuberculosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory tract infection viral
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Spinal cord infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Viral infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Abdominal wall abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bacteraemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Biliary sepsis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Blister infected
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bronchitis viral
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Campylobacter gastroenteritis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Candida pneumonia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Capnocytophaga sepsis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cardiac valve vegetation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cellulitis streptococcal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Coccidioidomycosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dengue fever
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Diverticulitis intestinal haemorrhagic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Endocarditis staphylococcal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Enterovirus infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Epstein-Barr virus infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Escherichia pyelonephritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Extradural abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Fungal infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gallbladder empyema
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastric ulcer helicobacter
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastroenteritis salmonella
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastrointestinal infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastrointestinal viral infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Giardiasis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Hepatitis E
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Hepatitis infectious mononucleosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Herpes zoster
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Human anaplasmosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Incision site abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infected bite
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infectious pleural effusion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infective aortitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infective exacerbation of asthma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infective exacerbation of bronchiectasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Joint abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Klebsiella sepsis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lower respiratory tract infection viral
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Mastitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Meningitis bacterial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Meningitis viral
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Neurosyphilis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Oral infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Osteomyelitis acute
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Otitis externa
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pelvic abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Periorbital cellulitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Perirectal abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Peritonsillar abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumococcal sepsis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia pneumococcal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia streptococcal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Post-acute COVID-19 syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Postoperative abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Renal abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory moniliasis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory syncytial virus bronchitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Rhinovirus infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Rotavirus infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Scrotal abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Scrotal cellulitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Scrotal infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sinusitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Skin infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Staphylococcal bacteraemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Streptococcal bacteraemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Submandibular abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tonsillitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Toxic shock syndrome streptococcal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Vestibular neuronitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Wound infection staphylococcal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrial fibrillation
|
0.53%
66/12503 • Number of events 77 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6226 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.50%
31/6243 • Number of events 35 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Myocardial infarction
|
0.43%
54/12503 • Number of events 56 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6226 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6243 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Coronary artery disease
|
0.30%
37/12503 • Number of events 38 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6243 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.22%
27/12503 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6243 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac failure
|
0.23%
29/12503 • Number of events 34 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.16%
20/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Angina pectoris
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Angina unstable
|
0.13%
16/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac arrest
|
0.11%
14/12503 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.10%
13/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrial flutter
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Acute coronary syndrome
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Arrhythmia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac failure acute
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Aortic valve stenosis
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Bradycardia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac failure chronic
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Left ventricular failure
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Pericarditis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrioventricular block complete
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Pericardial effusion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ventricular fibrillation
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac tamponade
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Dilated cardiomyopathy
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Heart failure with reduced ejection fraction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Palpitations
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Stress cardiomyopathy
|
0.02%
2/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Tachyarrhythmia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Aortic valve disease
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Aortic valve incompetence
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Bradyarrhythmia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiogenic shock
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiomegaly
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiopulmonary failure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiorenal syndrome
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Chronic coronary syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Right ventricular failure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Tricuspid valve incompetence
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Acute left ventricular failure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrial tachycardia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Bundle branch block left
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac valve disease
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiomyopathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Chordae tendinae rupture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Coronary artery aneurysm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Coronary artery embolism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Dressler's syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Extrasystoles
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Heart failure with preserved ejection fraction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Mitral valve calcification
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Mitral valve stenosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Nodal rhythm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Paroxysmal atrioventricular block
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Sinus arrest
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Supraventricular extrasystoles
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.31%
39/12503 • Number of events 39 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6226 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer recurrent
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatocellular carcinoma
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to liver
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer metastatic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial carcinoma
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell renal cell carcinoma
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive breast carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal carcinoma
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neoplasm
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic adenoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Throat cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer recurrent
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholangiocarcinoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive lobular breast carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of unknown primary site
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastasis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma of the skin
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal squamous cell carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of nipple
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary cystadenoma lymphomatosum
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer metastatic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue neoplasm malignant stage unspecified
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acoustic neuroma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia recurrent
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma gastric
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of appendix
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal adenoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign ovarian tumour
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct adenocarcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer recurrent
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder papilloma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma recurrent
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Borderline ovarian tumour
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm malignant
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer stage IV
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholesteatoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myelomonocytic leukaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer recurrent
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage III
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenocarcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer metastatic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage II
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Essential thrombocythaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type)
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicular lymphoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicular lymphoma stage IV
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage IV
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric neoplasm
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal lymphoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal stromal tumour
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma multiforme
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage III
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage I
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage IV
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal papillary-mucinous carcinoma of pancreas
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal proliferative breast lesion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyosarcoma metastatic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip squamous cell carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma metastatic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mediastinum neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medullary thyroid cancer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bladder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to chest wall
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to nervous system
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pancreas
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pelvis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peritoneum
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to rectum
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic lymphoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic malignant melanoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic renal cell carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic squamous cell carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myxoid liposarcoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibroma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage III
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage IV
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage IV
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal cancer metastatic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian adenoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage IV
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary thyroid cancer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pseudomyxoma peritonei
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer recurrent
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retroperitoneal neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Schwannoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Soft tissue sarcoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spindle cell sarcoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the hypopharynx
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteral neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.37%
46/12503 • Number of events 47 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6243 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Syncope
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6226 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.21%
26/12503 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Ischaemic stroke
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dizziness
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Loss of consciousness
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Seizure
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Sciatica
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral infarction
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Migraine
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Presyncope
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Transient global amnesia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Balance disorder
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Brain injury
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebellar infarction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral arteriosclerosis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral ischaemia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dementia Alzheimer's type
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Encephalopathy
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hypoglycaemic coma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Amyotrophic lateral sclerosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Ataxia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Carotid arteriosclerosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Carotid artery occlusion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebellar stroke
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dementia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Epilepsy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Facial paresis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Intracranial aneurysm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Myasthenia gravis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Nerve compression
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Radiculopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Aphasia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Arachnoiditis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Autonomic nervous system imbalance
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Bell's palsy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Brain stem haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Brain stem infarction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Brain stem stroke
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cauda equina syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebellar haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebellar syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral venous sinus thrombosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebrospinal fistula
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebrovascular disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cervical cord compression
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cervical radiculopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Demyelinating polyneuropathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Diplegia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dizziness postural
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dural arteriovenous fistula
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Embolic stroke
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Facial paralysis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hypertensive encephalopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hypoaesthesia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Intracranial haematoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Intraventricular haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Ischaemic cerebral infarction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Lacunar infarction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Lacunar stroke
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Lumbosacral radiculopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Mental impairment
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Myelin oligodendrocyte glycoprotein antibody-associated disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Neuroleptic malignant syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Occipital lobe stroke
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Occipital neuralgia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Parkinson's disease
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Peroneal nerve palsy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Psychogenic seizure
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Senile dementia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Somnolence
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Spinal claudication
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Thalamic infarction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Thalamus haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Thoracic radiculopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Thrombotic stroke
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Tremor
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Vertebral artery occlusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Vertebrobasilar artery dissection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Vertebrobasilar stroke
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fall
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.11%
14/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Incisional hernia
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Overdose
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ulna fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Multiple fractures
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Craniocerebral injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tendon injury
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fractured sacrum
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Injury
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Multiple injuries
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural haematoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Shoulder fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skull fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Acetabulum fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Comminuted fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Gun shot wound
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Jaw fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural hypotension
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Scapula fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Subcutaneous haematoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Anaemia postoperative
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Arthropod bite
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Bone contusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Coronary artery restenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Craniofacial fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Craniofacial injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Dislocation of vertebra
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Face injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Flail chest
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Forearm fracture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foreign body in eye
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Hypobarism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ilium fracture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Kidney rupture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ligament injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Muscle injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Periprosthetic fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural fever
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Postoperative hypertension
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Procedural complication
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Radiation injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Radiation pneumonitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Respiratory fume inhalation disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Spinal cord injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Spinal cord injury cervical
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Splenic injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Stab wound
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Subdural haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Traumatic arthrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Traumatic haemothorax
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Trunk injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ulnar nerve injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Urinary tract procedural complication
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Vascular injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Vulvovaginal injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Wound haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Wound necrosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.06%
8/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Colitis
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.04%
5/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Nausea
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Colitis ischaemic
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Duodenal ulcer haemorrhage
|
0.02%
2/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Vomiting
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Ileus
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic cyst
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Constipation
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Dysphagia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastric polyps
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal obstruction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Incarcerated umbilical hernia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Obstructive pancreatitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatitis chronic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatitis necrotising
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Peptic ulcer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Peptic ulcer perforation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal adhesions
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal wall haematoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Acute abdomen
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Appendix disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Barrett's oesophagus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Coeliac artery compression syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Colitis ulcerative
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Crohn's disease
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diverticular perforation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diverticulum
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diverticulum intestinal haemorrhagic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Duodenal ulcer perforation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Enterocolitis haemorrhagic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Epiploic appendagitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Food poisoning
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastric perforation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastric ulcer perforation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastritis haemorrhagic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal motility disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal necrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal vascular malformation haemorrhagic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary thrombosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma late onset
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma-chronic obstructive pulmonary disease overlap syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Asthmatic crisis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Choking
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Idiopathic pulmonary fibrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal polyp
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Lung perforation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Mediastinal mass
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Middle lobe syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal polyp
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary arterial hypertension
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum discoloured
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.38%
48/12503 • Number of events 52 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.61%
38/6226 • Number of events 41 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6243 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bone cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteoporotic fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Vertebral foraminal stenosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bone lesion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Cervical spinal stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Diastasis recti abdominis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Haemarthrosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Pseudarthrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff tear arthropathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Sacral pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Soft tissue mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal synovial cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spondylitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spondyloarthropathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Trigger finger
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Death
|
0.43%
54/12503 • Number of events 54 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6226 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.45%
28/6243 • Number of events 28 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Chest pain
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Asthenia
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Sudden death
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Non-cardiac chest pain
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Chest discomfort
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Oedema peripheral
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Sudden cardiac death
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Impaired healing
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Pyrexia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Accidental death
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Adverse drug reaction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Cardiac death
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Cyst rupture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
General physical health deterioration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Influenza like illness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Oedema
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Peripheral swelling
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Drowning
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Drug resistance
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Drug withdrawal syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Gait disturbance
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Gait inability
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Generalised oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Hyperthermia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Ill-defined disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Malaise
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Nodule
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Obstruction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Pelvic mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Swelling face
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vascular stent occlusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypertension
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic stenosis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Deep vein thrombosis
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral ischaemia
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypertensive crisis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypotension
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Circulatory collapse
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Haematoma
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic aneurysm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Giant cell arteritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic aneurysm rupture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Extremity necrosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Thrombosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic dissection
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral venous disease
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aneurysm ruptured
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Arteriosclerosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypertensive emergency
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypertensive urgency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Iliac artery occlusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Internal haemorrhage
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral artery occlusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral artery stenosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral artery thrombosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Shock haemorrhagic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Accelerated hypertension
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aneurysm
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Arterial rupture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Embolism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Essential hypertension
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Femoral artery aneurysm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Iliac artery stenosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Malignant hypertension
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Pelvic venous thrombosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral artery aneurysm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Scalp haematoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Subclavian steal syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Subclavian vein thrombosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Varicose vein
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Vasculitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Venous thrombosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Venous thrombosis limb
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.14%
18/12503 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal failure
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary retention
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Haematuria
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Cystitis haemorrhagic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Haemorrhage urinary tract
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Stress urinary incontinence
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Bladder disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Bladder stenosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Bladder tamponade
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Calculus bladder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Calculus urinary
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Nephropathy toxic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Obstructive nephropathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Ureteral necrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Ureteric obstruction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary bladder haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.05%
6/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Diabetic ketoacidosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Diabetic complication
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Gout
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Acidosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Diabetic metabolic decompensation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Euglycaemic diabetic ketoacidosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Fluid retention
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperchloraemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperglycaemic hyperosmolar nonketotic syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypophagia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Type 1 diabetes mellitus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Biliary colic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholangitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Jaundice cholestatic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Biliary tract disorder
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholangitis acute
|
0.02%
2/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Gallbladder rupture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic cirrhosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic failure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Biliary dilatation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Biliary obstruction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholelithiasis obstructive
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic function abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic steatosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Jaundice
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Depression
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Confusional state
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Alcoholism
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Mental status changes
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Delirium
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Alcohol withdrawal syndrome
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Suicidal ideation
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Suicide attempt
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Bipolar disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Completed suicide
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Anxiety
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Mental disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Adjustment disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Adjustment disorder with depressed mood
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Bipolar I disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Conversion disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Depressed mood
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Gender dysphoria
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Hallucination, visual
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Hallucinations, mixed
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Mania
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Panic attack
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Post-traumatic stress disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Substance-induced mood disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Blood loss anaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Endometrial hyperplasia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Genital prolapse
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Uterine prolapse
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Adnexa uteri cyst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Breast hyperplasia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Cervical dysplasia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Cystocele
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Ovarian cyst ruptured
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Pelvic organ prolapse
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Postmenopausal haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatic cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatic dysplasia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatic obstruction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Rectocele
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Scrotal swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Uterine polyp
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Cataract
|
0.11%
14/12503 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Glaucoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Ocular myasthenia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal detachment
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal vein occlusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Blepharochalasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Blindness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Blindness transient
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Corneal decompensation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Corneal erosion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Episcleritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eyelid cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Macular degeneration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Ocular hyperaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal tear
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinoschisis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Immune thrombocytopenia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Microcytic anaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Hypochromic anaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Increased tendency to bruise
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Diabetic foot
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Subcutaneous emphysema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Henoch-Schonlein purpura
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Hypersensitivity vasculitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pemphigoid
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pemphigus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash vesicular
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin necrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Stasis dermatitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Stevens-Johnson syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Superficial inflammatory dermatosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Toxic skin eruption
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood pressure increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Oxygen saturation decreased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood electrolytes abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood glucose increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Hepatic enzyme increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
International normalised ratio fluctuation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Myocardial necrosis marker increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Pulse absent
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Troponin increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Goitre
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Thyroid mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Adrenal mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Cushing's syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Hyperparathyroidism
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Hypothyroidism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Inappropriate antidiuretic hormone secretion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Pituitary-dependent Cushing's syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Anaphylactic reaction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Allergy to arthropod bite
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Anaphylactic shock
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Anti-neutrophil cytoplasmic antibody positive vasculitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Primary amyloidosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Sarcoidosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Hypertrophic cardiomyopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Corneal dystrophy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Hereditary haemorrhagic telangiectasia
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Hereditary non-polyposis colorectal cancer syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Hydrocele
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Phimosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Ventricular septal defect
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Vertigo
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Deafness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Neurosensory hypoacusis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Product Issues
Device dislocation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Product Issues
Device loosening
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Product Issues
Device breakage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Product Issues
Device malfunction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Surgical and medical procedures
Assisted suicide
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
Other adverse events
| Measure |
Placebo Group
n=12503 participants at risk
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year.
|
RSV_1_dose Group
n=6226 participants at risk
Participants received a dose of placebo every subsequent year.
|
RSV_annual Group
n=6243 participants at risk
Participants received an additional dose of RSVPreF3 OA vaccine every subsequent year
|
|---|---|---|---|
|
Skin and subcutaneous tissue disorders
Onychoclasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin reaction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Alopecia scarring
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Androgenetic alopecia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermatitis bullous
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Eczema asteatotic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Eczema nummular
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Hidradenitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Keloid scar
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Lentigo
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Lichen planopilaris
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Mechanical urticaria
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Milia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Myxoid cyst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Nail bed bleeding
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Nail bed inflammation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Nail ridging
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Fatigue
|
3.3%
410/12503 • Number of events 469 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
6.3%
394/6226 • Number of events 446 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
7.3%
453/6243 • Number of events 541 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site erythema
|
0.45%
56/12503 • Number of events 60 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
4.7%
291/6226 • Number of events 299 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
7.2%
449/6243 • Number of events 522 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site swelling
|
0.30%
38/12503 • Number of events 38 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
3.3%
208/6226 • Number of events 211 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
5.6%
347/6243 • Number of events 406 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Pyrexia
|
0.68%
85/12503 • Number of events 89 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
2.3%
144/6226 • Number of events 149 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
3.2%
197/6243 • Number of events 217 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Pain
|
0.61%
76/12503 • Number of events 78 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.2%
76/6226 • Number of events 76 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.9%
120/6243 • Number of events 129 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Chills
|
0.37%
46/12503 • Number of events 51 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.72%
45/6226 • Number of events 45 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.7%
104/6243 • Number of events 113 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site pain
|
0.14%
18/12503 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.1%
66/6226 • Number of events 67 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.4%
86/6243 • Number of events 95 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site pruritus
|
0.19%
24/12503 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.66%
41/6226 • Number of events 41 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.3%
84/6243 • Number of events 90 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Malaise
|
0.27%
34/12503 • Number of events 37 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.56%
35/6226 • Number of events 38 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.1%
69/6243 • Number of events 73 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Asthenia
|
0.29%
36/12503 • Number of events 36 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.64%
40/6226 • Number of events 41 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.88%
55/6243 • Number of events 58 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site warmth
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.66%
41/6226 • Number of events 43 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.2%
78/6243 • Number of events 85 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site joint pain
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.59%
37/6226 • Number of events 40 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.80%
50/6243 • Number of events 52 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site pain
|
0.06%
8/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.47%
29/6226 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.86%
54/6243 • Number of events 64 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site reaction
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.47%
29/6226 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.62%
39/6243 • Number of events 46 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site bruising
|
0.20%
25/12503 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6226 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.48%
30/6243 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Chest pain
|
0.22%
27/12503 • Number of events 28 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.40%
25/6226 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Feeling hot
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6226 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.53%
33/6243 • Number of events 33 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Oedema peripheral
|
0.22%
27/12503 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Influenza like illness
|
0.21%
26/12503 • Number of events 26 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site discomfort
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.38%
24/6243 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Peripheral swelling
|
0.15%
19/12503 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site induration
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6243 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site erythema
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6243 • Number of events 26 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.38%
24/6243 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Chest discomfort
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6243 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Feeling cold
|
0.05%
6/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site inflammation
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site rash
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Discomfort
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site haematoma
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site erythema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Swelling
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Axillary pain
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Cyst
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site movement impairment
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site mass
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site swelling
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site pruritus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site hypoaesthesia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site reaction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Adverse drug reaction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Non-cardiac chest pain
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site hyperaesthesia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Swelling face
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Feeling abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site haemorrhage
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site bruising
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Hernia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Illness
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site hypersensitivity
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site paraesthesia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site warmth
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site warmth
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Gait disturbance
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site lymphadenopathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site nodule
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Oedema
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Temperature regulation disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vessel puncture site bruise
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Ill-defined disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site urticaria
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site joint pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Facial pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Feeling of body temperature change
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site extravasation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site irritation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Mass
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Nodule
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Precancerous condition
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Puncture site erythema
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Puncture site pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Secretion discharge
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Thirst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site inflammation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site movement impairment
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Oral herpes
|
0.25%
31/12503 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6226 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6243 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site bruise
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site pruritus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Calcinosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Complication associated with device
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Granuloma
|
0.02%
2/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Gravitational oedema
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site discolouration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site joint discomfort
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Sensation of foreign body
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site discolouration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site discomfort
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site haematoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site rash
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vessel puncture site pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Administration site papule
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Application site pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Application site warmth
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Chronic fatigue syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Drug intolerance
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Exercise tolerance decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Face oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Fat necrosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Fat tissue increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Fibrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
General physical health deterioration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Hyperthermia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Impaired healing
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site coldness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site dermatitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site joint movement impairment
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site joint swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site scab
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Local reaction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Localised oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Medical device pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Meteoropathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Pelvic mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Puncture site swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Sluggishness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Suprapubic pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Systemic inflammatory response syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Ulcer haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site joint pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site joint swelling
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vaccination site paraesthesia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vessel puncture site haematoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vessel puncture site haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vessel puncture site reaction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Vessel puncture site swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Withdrawal syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
COVID-19
|
9.4%
1178/12503 • Number of events 1283 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
9.6%
600/6226 • Number of events 656 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
9.6%
601/6243 • Number of events 647 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Upper respiratory tract infection
|
4.2%
526/12503 • Number of events 638 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
3.9%
244/6226 • Number of events 288 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
3.9%
243/6243 • Number of events 298 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bronchitis
|
1.6%
204/12503 • Number of events 220 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
2.0%
126/6226 • Number of events 139 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.6%
99/6243 • Number of events 103 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Urinary tract infection
|
1.5%
184/12503 • Number of events 214 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.4%
85/6226 • Number of events 95 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.5%
92/6243 • Number of events 106 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Nasopharyngitis
|
1.4%
178/12503 • Number of events 190 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.4%
90/6226 • Number of events 96 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.4%
89/6243 • Number of events 92 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory tract infection
|
0.74%
93/12503 • Number of events 96 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.87%
54/6226 • Number of events 59 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.85%
53/6243 • Number of events 57 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sinusitis
|
0.72%
90/12503 • Number of events 97 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.67%
42/6226 • Number of events 44 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.74%
46/6243 • Number of events 51 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.49%
61/12503 • Number of events 66 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.39%
24/6226 • Number of events 26 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.50%
31/6243 • Number of events 35 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Rhinitis
|
0.42%
52/12503 • Number of events 52 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.45%
28/6226 • Number of events 33 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.48%
30/6243 • Number of events 32 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia
|
0.49%
61/12503 • Number of events 62 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.47%
29/6226 • Number of events 29 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.30%
19/6243 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.38%
48/12503 • Number of events 55 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.45%
28/6226 • Number of events 32 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.40%
25/6243 • Number of events 35 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Herpes zoster
|
0.39%
49/12503 • Number of events 52 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6226 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.50%
31/6243 • Number of events 32 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cystitis
|
0.34%
43/12503 • Number of events 45 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6226 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6243 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastroenteritis
|
0.29%
36/12503 • Number of events 36 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.40%
25/6226 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Influenza
|
0.24%
30/12503 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6226 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.38%
24/6243 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cellulitis
|
0.27%
34/12503 • Number of events 36 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6243 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Conjunctivitis
|
0.26%
33/12503 • Number of events 34 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.30%
19/6243 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Ear infection
|
0.23%
29/12503 • Number of events 32 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tooth infection
|
0.22%
27/12503 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6226 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tooth abscess
|
0.21%
26/12503 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Diverticulitis
|
0.18%
23/12503 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pharyngitis
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory tract infection viral
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Localised infection
|
0.12%
15/12503 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Acute sinusitis
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Suspected COVID-19
|
0.11%
14/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gingivitis
|
0.08%
10/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Viral infection
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Otitis media
|
0.08%
10/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Hordeolum
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Laryngitis
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lower respiratory tract infection viral
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Otitis externa
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastroenteritis viral
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Eye infection
|
0.05%
6/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Fungal infection
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Helicobacter infection
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Kidney infection
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Onychomycosis
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Periodontitis
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Herpes simplex
|
0.06%
8/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Paronychia
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Skin infection
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Candida infection
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Erysipelas
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Oral candidiasis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Vulvovaginal candidiasis
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Wound infection
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lower respiratory tract infection bacterial
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pharyngitis streptococcal
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Post-acute COVID-19 syndrome
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tinea pedis
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Chronic sinusitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lyme disease
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tracheobronchitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bronchitis viral
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Fungal skin infection
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Furuncle
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastrointestinal infection
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Herpes virus infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infective exacerbation of asthma
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Otitis media acute
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Post procedural infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pulpitis dental
|
0.03%
4/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory syncytial virus infection
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Rhinovirus infection
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Acarodermatitis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infected bite
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Postoperative wound infection
|
0.03%
4/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Staphylococcal infection
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tonsillitis
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Folliculitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Nail infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pulmonary tuberculosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tinea cruris
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tracheitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bacterial vaginosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastrointestinal viral infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Impetigo
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infected dermal cyst
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infected skin ulcer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pyelonephritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Subcutaneous abscess
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Vaginal infection
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Viral pharyngitis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Vulvitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Abscess oral
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Arthritis infective
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Body tinea
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Breast abscess
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Clostridium difficile infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Device related infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Fungal foot infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Genital infection fungal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Helicobacter gastritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Hepatitis C
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infected cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Latent tuberculosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Nail bed infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Orchitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Urethritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Viral sinusitis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Abscess limb
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bronchitis bacterial
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Campylobacter gastroenteritis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Conjunctivitis bacterial
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dermatophytosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dermatophytosis of nail
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dientamoeba infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dysentery
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Eczema infected
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Enterovirus infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Epididymitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Escherichia infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Fungal oesophagitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastric infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Groin abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Labyrinthitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Laryngitis bacterial
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Laryngopharyngitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Norovirus infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Oropharyngeal candidiasis
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Osteomyelitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Otitis media chronic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pertussis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia aspiration
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Root canal infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Salmonellosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sepsis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sialoadenitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sinusitis bacterial
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Staphylococcal skin infection
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tinea infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Viral rhinitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Acariasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Anal abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Appendicitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Atypical pneumonia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bacterial infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Bronchiolitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Campylobacter infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Chlamydial infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Conjunctivitis viral
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Coronavirus infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Cytomegalovirus infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dengue fever
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dental gangrene
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Dermatitis infected
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Diabetic foot infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Diarrhoea infectious
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Enterobacter infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Enterobiasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Escherichia pyelonephritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Eyelid infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Fungal pharyngitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gangrene
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastrointestinal bacterial infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gastrointestinal bacterial overgrowth
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Genital infection bacterial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Gingival abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
HIV infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Haemophilus infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Haemorrhoid infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Herpangina
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Herpes ophthalmic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Histoplasmosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Injection site pustule
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Large intestine infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Laryngitis viral
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lyme arthritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Lymphangitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Mycoplasma infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Myiasis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Nasal vestibulitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Oesophageal candidiasis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Ophthalmic herpes zoster
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Oral fungal infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Oral infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Otitis externa fungal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Parotitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Penile infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Perineal abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Peritonsillar abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pilonidal disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia bacterial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia fungal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pneumonia mycoplasmal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Postoperative abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Prostate infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pyelonephritis acute
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pyonephrosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Pyuria
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Rectal abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Respiratory syncytial virus bronchitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Retinitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Rocky mountain spotted fever
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Scarlet fever
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sebaceous gland infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Shigella infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Sinobronchitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Skin graft infection
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
General disorders
Injection site pain
|
3.4%
424/12503 • Number of events 469 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
22.1%
1379/6226 • Number of events 1462 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
27.4%
1713/6243 • Number of events 2257 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Staphylococcal abscess
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Stenotrophomonas infection
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Streptococcal bacteraemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Superinfection bacterial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Tinea versicolour
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Urinary tract infection bacterial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Varicella
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Vestibular neuronitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Vulval abscess
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Infections and infestations
Wound infection bacterial
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Headache
|
5.7%
710/12503 • Number of events 856 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
9.5%
594/6226 • Number of events 712 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
10.6%
664/6243 • Number of events 820 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dizziness
|
0.84%
105/12503 • Number of events 112 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.1%
66/6226 • Number of events 73 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.4%
88/6243 • Number of events 91 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Sciatica
|
0.34%
43/12503 • Number of events 44 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6226 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6243 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Lethargy
|
0.11%
14/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.31%
19/6226 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Syncope
|
0.16%
20/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Paraesthesia
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Migraine
|
0.16%
20/12503 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hypoaesthesia
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.15%
19/12503 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.13%
16/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Somnolence
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Tremor
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cognitive disorder
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dementia
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Sinus headache
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Amnesia
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Nerve compression
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dysgeusia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Tension headache
|
0.06%
8/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Diabetic neuropathy
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Neuralgia
|
0.05%
6/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Balance disorder
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Presyncope
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Restless legs syndrome
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dementia Alzheimer's type
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Bell's palsy
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Parkinson's disease
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Memory impairment
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Brain fog
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Head discomfort
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Radiculopathy
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Ageusia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Burning sensation
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cervical radiculopathy
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Loss of consciousness
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cervicobrachial syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Disturbance in attention
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dysarthria
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Intercostal neuralgia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Intracranial aneurysm
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Ophthalmic migraine
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Polyneuropathy
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Post-traumatic headache
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Trigeminal neuralgia
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Anosmia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Carotid arteriosclerosis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cluster headache
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Essential tremor
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hypersomnia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Myasthenia gravis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Parkinsonism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Peroneal nerve palsy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral small vessel ischaemic disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dizziness postural
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hydrocephalus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Nervous system disorder
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Peripheral sensorimotor neuropathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Petit mal epilepsy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Post herpetic neuralgia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Resting tremor
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Seizure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Tardive dyskinesia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Amnestic disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Apraxia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Axonal and demyelinating polyneuropathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Axonal neuropathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Brain hypoxia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebellar atrophy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral amyloid angiopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral infarction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebral ischaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Cerebrovascular disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Coordination abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Crocodile tears syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dementia of the Alzheimer's type, uncomplicated
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Drooling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Salivary gland calculus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dural arteriovenous fistula
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Dyskinesia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Facial spasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Formication
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hyposmia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Hypotonia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
IVth nerve paralysis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Mental impairment
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Micrographia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Monoparesis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Motor dysfunction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Movement disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Myoclonus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Occipital neuralgia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Parosmia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Peripheral nerve paresis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Sensory disturbance
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Sensory loss
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Sleep deficit
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Spasmodic dysphonia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Spinal claudication
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Taste disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Thunderclap headache
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Toxic neuropathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Transient global amnesia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Vertebrobasilar insufficiency
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Nervous system disorders
Vestibular migraine
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
2.4%
299/12503 • Number of events 343 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
3.6%
226/6226 • Number of events 245 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
4.2%
261/6243 • Number of events 300 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
1.6%
205/12503 • Number of events 237 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
3.7%
228/6226 • Number of events 249 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
4.9%
307/6243 • Number of events 362 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
1.4%
181/12503 • Number of events 195 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.4%
87/6226 • Number of events 91 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.5%
93/6243 • Number of events 100 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.78%
98/12503 • Number of events 103 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.3%
82/6226 • Number of events 89 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.5%
91/6243 • Number of events 99 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.69%
86/12503 • Number of events 86 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.79%
49/6226 • Number of events 49 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.85%
53/6243 • Number of events 57 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.41%
51/12503 • Number of events 52 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.40%
25/6226 • Number of events 28 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.56%
35/6243 • Number of events 36 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.26%
33/12503 • Number of events 34 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6226 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6243 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.21%
26/12503 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6226 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.24%
30/12503 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.18%
22/12503 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.12%
15/12503 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6243 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.18%
22/12503 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteopenia
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.12%
15/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.13%
16/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.11%
14/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.08%
10/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Trigger finger
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Exostosis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Psoriatic arthropathy
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscle tightness
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Tendon disorder
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's contracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Fibromyalgia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Greater trochanteric pain syndrome
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Scoliosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Sacral pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Sacroiliitis
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Temporomandibular pain and dysfunction syndrome
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc compression
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint stiffness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Mobility decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscle contracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteochondrosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Polyarthritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Sacroiliac joint dysfunction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Arthritis reactive
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Axillary mass
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Cervical spinal stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Clubbing
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Diastasis recti abdominis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Meniscopathy
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscle fatigue
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Palindromic rheumatism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Sjogren's syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Systemic lupus erythematosus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Vertebral foraminal stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Ankylosing spondylitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Articular calcification
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Back disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bone callus excessive
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bone disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Bone loss
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Chondritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Chondropathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Coccydynia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Diffuse idiopathic skeletal hyperostosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Enthesopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Exostosis of jaw
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Gouty tophus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Infrapatellar fat pad inflammation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc annular tear
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint hyperextension
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint instability
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Joint lock
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Ligament pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Limb deformity
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Mastication disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Metatarsalgia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscle discomfort
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Muscle swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Neck mass
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Osteomalacia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Polychondritis
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Rheumatic disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Scleroderma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Seronegative arthritis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Sinus tarsi syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Soft tissue mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spinal ligament ossification
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spondylitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Tendon pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis stenosans
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Musculoskeletal and connective tissue disorders
Torticollis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
1.8%
229/12503 • Number of events 241 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
2.1%
128/6226 • Number of events 139 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
2.2%
135/6243 • Number of events 143 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
1.6%
202/12503 • Number of events 225 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
2.3%
141/6226 • Number of events 156 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
2.0%
127/6243 • Number of events 133 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
1.6%
194/12503 • Number of events 208 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.9%
121/6226 • Number of events 127 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.4%
88/6243 • Number of events 101 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.78%
98/12503 • Number of events 108 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.82%
51/6226 • Number of events 53 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.82%
51/6243 • Number of events 53 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.57%
71/12503 • Number of events 90 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.53%
33/6226 • Number of events 38 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.59%
37/6243 • Number of events 44 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.43%
54/12503 • Number of events 62 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.50%
31/6226 • Number of events 41 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6243 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.42%
53/12503 • Number of events 56 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6226 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.46%
29/6243 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.34%
42/12503 • Number of events 44 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.48%
30/6226 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.43%
27/6243 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.34%
42/12503 • Number of events 42 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.48%
30/6243 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory disorder
|
0.35%
44/12503 • Number of events 46 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.40%
25/6226 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6243 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.23%
29/12503 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.14%
18/12503 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6243 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.12%
15/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.12%
15/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.08%
10/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Dry throat
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Increased upper airway secretion
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus discomfort
|
0.03%
4/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum increased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Lower respiratory tract congestion
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus pain
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract inflammation
|
0.03%
4/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Aphonia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal discomfort
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary congestion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory tract congestion
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial hyperreactivity
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Catarrh
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal discomfort
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal obstruction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal polyps
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Obstructive sleep apnoea syndrome
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Painful respiration
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus hypersecretion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Increased bronchial secretion
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal pruritus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal swelling
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Reflux laryngitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Idiopathic pulmonary fibrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Lung consolidation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Orthopnoea
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary arterial hypertension
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary thrombosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory symptom
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinalgia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Adenoidal hypertrophy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Allergic cough
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Allergic sinusitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma exercise induced
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma-chronic obstructive pulmonary disease overlap syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial wall thickening
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Choking sensation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Cystic lung disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Epiglottic cyst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Hyperventilation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngospasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Lung hyperinflation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Lung opacity
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal cavity mass
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal crusting
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal cyst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal dryness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal septum deviation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal ulcer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Neurogenic cough
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Nocturnal dyspnoea
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Obstructive airways disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal paraesthesia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal ulceration
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural fibrosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural thickening
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Rhonchi
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sinonasal obstruction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum discoloured
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum retention
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Suffocation feeling
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Throat clearing
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Throat lesion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Tonsillar cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Tonsillar hypertrophy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Tracheal inflammation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Upper airway obstruction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract congestion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Vasomotor rhinitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Vocal cord polyp
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diarrhoea
|
1.7%
217/12503 • Number of events 230 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.9%
119/6226 • Number of events 129 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.7%
107/6243 • Number of events 110 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Nausea
|
0.56%
70/12503 • Number of events 72 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.1%
70/6226 • Number of events 73 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.2%
76/6243 • Number of events 79 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Vomiting
|
0.41%
51/12503 • Number of events 53 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.45%
28/6226 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.43%
27/6243 • Number of events 27 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.38%
47/12503 • Number of events 51 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6226 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.46%
29/6243 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.41%
51/12503 • Number of events 51 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.50%
31/6243 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.30%
38/12503 • Number of events 41 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.39%
24/6226 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6243 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Toothache
|
0.28%
35/12503 • Number of events 35 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6226 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.30%
19/6243 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Constipation
|
0.20%
25/12503 • Number of events 28 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6226 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6243 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.19%
24/12503 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastritis
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Dental caries
|
0.17%
21/12503 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.11%
14/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.08%
10/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Dry mouth
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Dysphagia
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Food poisoning
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Colitis
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Flatulence
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diverticulum
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Anal fissure
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Anal incontinence
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Frequent bowel movements
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gingival pain
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Colitis microscopic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Colitis ulcerative
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal pain
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Haematochezia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Impaired gastric emptying
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Odynophagia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Salivary hypersecretion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Stomatitis
|
0.02%
3/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Barrett's oesophagus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Crohn's disease
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Faeces soft
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastritis erosive
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Glossodynia
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Periodontal disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Aphthous ulcer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Enteritis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Haematemesis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Intestinal polyp
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Melaena
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic cyst
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic failure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Peptic ulcer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Bile acid malabsorption
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Coeliac disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Epiploic appendagitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal angiodysplasia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastrointestinal tract irritation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gingival disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Glossitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Lip pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Noninfective gingivitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oral disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatitis chronic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pharyngo-oesophageal diverticulum
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Rectal polyp
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Rectal tenesmus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Regurgitation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Swollen tongue
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal symptom
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abdominal tenderness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Abnormal faeces
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Anal eczema
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Anal fistula
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Angular cheilitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Anorectal discomfort
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Appendix disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Ascites
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Diverticulum oesophageal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Duodenal polyp
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Duodenitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Duodenogastric reflux
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Erosive oesophagitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastric cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gastric polyps
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gingival recession
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gingival swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Gingival ulceration
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Inflammatory bowel disease
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Lip disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Malabsorption
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Mechanical ileus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Mesenteric artery stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophageal achalasia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophageal disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oral mucosal exfoliation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Oral papule
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic mass
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic pseudocyst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatic steatosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Parotid gland enlargement
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Precancerous lesion of digestive tract
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Proctitis ulcerative
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Pyloric sphincter insufficiency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Reflux gastritis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Salivary duct obstruction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Salivary gland pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Steatorrhoea
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Tongue coated
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Tongue disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Tongue dry
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Tongue ulceration
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Tooth deposit
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Gastrointestinal disorders
Tooth disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fall
|
0.43%
54/12503 • Number of events 55 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.45%
28/6226 • Number of events 28 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.48%
30/6243 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.36%
45/12503 • Number of events 46 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6226 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6243 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Arthropod bite
|
0.18%
23/12503 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6226 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6243 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.23%
29/12503 • Number of events 30 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6226 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.20%
25/12503 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6226 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6226 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.19%
24/12503 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.17%
21/12503 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.13%
16/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Immunisation reaction
|
0.10%
13/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.13%
16/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Arthropod sting
|
0.10%
13/12503 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.13%
16/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.07%
9/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Craniofacial fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Bone contusion
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Muscle rupture
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Eye injury
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.04%
5/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Epicondylitis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Eye contusion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Face injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post-traumatic neck syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Back injury
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Burns second degree
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Corneal abrasion
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Exposure to SARS-CoV-2
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Stress fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Wound
|
0.02%
2/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Muscle injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Musculoskeletal foreign body
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Synovial rupture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tendon injury
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ulna fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Forearm fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foreign body in eye
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foreign body in throat
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Fractured coccyx
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Heat illness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Hypobarism
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Injury
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Jaw fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Ligament injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Lip injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Multiple injuries
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Muscle contusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.02%
2/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural contusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Radiation injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Scapula fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Spinal column injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Sternal fracture
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Sunburn
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Tooth injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Avulsion fracture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Bite
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Bone fragmentation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Burn oral cavity
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Chemical burns of eye
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Chillblains
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Corneal epithelial downgrowth
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Craniocerebral injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Dental restoration failure
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Electric shock
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Exposure to toxic agent
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Extradural haematoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foreign body in ear
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foreign body in gastrointestinal tract
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Foreign body in respiratory tract
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Hyphaema
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Iliotibial band syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Injection related reaction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Metal poisoning
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Mouth injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Multiple fractures
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Musculoskeletal injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Neck injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Nerve injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Open fracture
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Overdose
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Penis injury
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Periprocedural myocardial infarction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post procedural haematuria
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Post-traumatic pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Procedural dizziness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Procedural nausea
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Procedural vomiting
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Pulmonary contusion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Radiation pneumonitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Renal transplant failure
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Scar
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Seroma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skeletal injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skin wound
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skull fracture
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Skull fractured base
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Snake bite
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Sports injury
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Stoma site haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Injury, poisoning and procedural complications
Venomous sting
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypertension
|
2.0%
246/12503 • Number of events 250 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.8%
110/6226 • Number of events 111 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
1.7%
107/6243 • Number of events 110 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypotension
|
0.15%
19/12503 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Haematoma
|
0.11%
14/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hot flush
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Deep vein thrombosis
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral venous disease
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Varicose vein
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Thrombosis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic aneurysm
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic arteriosclerosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic stenosis
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Flushing
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypertensive crisis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Phlebitis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Lymphoedema
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Orthostatic hypotension
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Thrombophlebitis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Arteriosclerosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Blood pressure fluctuation
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Essential hypertension
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral coldness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Giant cell arteritis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Raynaud's phenomenon
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
White coat hypertension
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic dilatation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Intermittent claudication
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral artery occlusion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Aortic disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Bleeding varicose vein
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Blood pressure inadequately controlled
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Embolism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Hypertensive urgency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Microscopic polyangiitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Peripheral ischaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Phlebectasia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Phlebitis superficial
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Subclavian steal syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Superficial vein thrombosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Systolic hypertension
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Varicose ulceration
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Vasodilatation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Vascular disorders
Vena cava thrombosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.44%
55/12503 • Number of events 56 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6226 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.62%
39/6243 • Number of events 39 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.48%
60/12503 • Number of events 60 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.39%
24/6226 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6243 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Gout
|
0.29%
36/12503 • Number of events 38 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.31%
19/6226 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6243 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.31%
39/12503 • Number of events 39 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6243 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.19%
24/12503 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.31%
19/6226 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6243 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6243 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.16%
20/12503 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6226 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Dyslipidaemia
|
0.16%
20/12503 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Vitamin B12 deficiency
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.03%
4/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Folate deficiency
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Impaired fasting glucose
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Insulin resistance
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Polydipsia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Vitamin B complex deficiency
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Calcium deficiency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Enzyme abnormality
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Gluten sensitivity
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Hypovitaminosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Increased appetite
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Lactose intolerance
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Lipoedema
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Magnesium deficiency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Overweight
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Vitamin B1 deficiency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Metabolism and nutrition disorders
Vitamin B6 deficiency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.29%
36/12503 • Number of events 36 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.50%
31/6226 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.58%
36/6243 • Number of events 36 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.27%
34/12503 • Number of events 34 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.39%
24/6226 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.27%
17/6243 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.12%
15/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.19%
12/6226 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.09%
11/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.10%
13/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.06%
8/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.02%
3/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Ingrowing nail
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.05%
6/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Hand dermatitis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Lichen planus
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Seborrhoeic dermatitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin irritation
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dermatitis atopic
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Lichen sclerosus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Precancerous skin lesion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash papular
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin warm
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Blood blister
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Cold sweat
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Cutaneous lupus erythematosus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Diabetic foot
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Excessive granulation tissue
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Granuloma annulare
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Haemorrhage subcutaneous
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Intertrigo
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Miliaria
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Neurodermatitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rosacea
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Sensitive skin
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Onychogryphosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Onycholysis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Papule
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pemphigus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Perioral dermatitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Photodermatosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pigmentation disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pityriasis rosea
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Prurigo
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Pruritus allergic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Purpura senile
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Rash vesicular
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Sebaceous gland disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin erosion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin fissures
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin lesion inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Skin mass
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Spider naevus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Telangiectasia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Transient acantholytic dermatosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Skin and subcutaneous tissue disorders
Vitiligo
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrial fibrillation
|
0.72%
90/12503 • Number of events 96 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.56%
35/6226 • Number of events 36 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.51%
32/6243 • Number of events 33 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Palpitations
|
0.16%
20/12503 • Number of events 22 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Angina pectoris
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Tachycardia
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Bradycardia
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Coronary artery disease
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Arrhythmia
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac failure
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Extrasystoles
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrial flutter
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac failure chronic
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Supraventricular extrasystoles
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Tricuspid valve incompetence
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Angina unstable
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Aortic valve incompetence
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Bundle branch block right
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiomegaly
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiovascular disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Myocardial infarction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Sinus bradycardia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Tachycardia paroxysmal
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrial tachycardia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiomyopathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Chronic coronary syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Heart failure with reduced ejection fraction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Heart valve incompetence
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Mitral valve calcification
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Mitral valve prolapse
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Mitral valve stenosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Aortic valve calcification
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Aortic valve stenosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Bundle branch block
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Bundle branch block left
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac valve disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Cardiac ventricular thrombosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Diastolic dysfunction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Dilated cardiomyopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ischaemic cardiomyopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Left ventricular hypertrophy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Myocarditis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Myopericarditis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Pericarditis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Prinzmetal angina
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Right ventricular hypertrophy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Sinoatrial block
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Tachyarrhythmia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Cardiac disorders
Wolff-Parkinson-White syndrome
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Cataract
|
0.45%
56/12503 • Number of events 63 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.31%
19/6226 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.35%
22/6243 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye pain
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Glaucoma
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Dry eye
|
0.11%
14/12503 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Lacrimation increased
|
0.10%
13/12503 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Macular degeneration
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye pruritus
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Blepharitis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Vision blurred
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal detachment
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Vitreous detachment
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Ocular hyperaemia
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal tear
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Visual impairment
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Conjunctivitis allergic
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye discharge
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye irritation
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Diplopia
|
0.03%
4/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Epiretinal membrane
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye disorder
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye swelling
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Vitreous floaters
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Asthenopia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Diabetic retinopathy
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eyelid ptosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Macular hole
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Neovascular age-related macular degeneration
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Posterior capsule opacification
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal artery occlusion
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Swelling of eyelid
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Dacryostenosis acquired
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Entropion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye allergy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eyelid cyst
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eyelid pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Keratitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Photophobia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Photopsia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Ulcerative keratitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Uveitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Visual acuity reduced
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Abnormal sensation in eye
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Blepharospasm
|
0.01%
1/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Blindness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Cataract nuclear
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Choroidal neovascularisation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Dermatochalasis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Dry age-related macular degeneration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eczema eyelids
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Erythema of eyelid
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye degenerative disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye haematoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eye ulcer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eyelid margin crusting
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eyelid skin dryness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Eyelids pruritus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Iridocyclitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Lacrimal fistula
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Macular scar
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Maculopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Meibomian gland dysfunction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Metamorphopsia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Narrow anterior chamber angle
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Ocular discomfort
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Ocular hypertension
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Optic nerve sheath haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Periorbital swelling
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Pinguecula
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Pterygium
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal degeneration
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal infarction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal neovascularisation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal oedema
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinal vascular thrombosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Retinopathy hypertensive
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Scleral hyperaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Scleritis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Trichiasis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Visual field defect
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Vitreous haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Eye disorders
Vitreous opacities
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Body temperature increased
|
0.04%
5/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6226 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.62%
39/6243 • Number of events 42 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood pressure increased
|
0.25%
31/12503 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
SARS-CoV-2 test positive
|
0.14%
17/12503 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6243 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Weight decreased
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6226 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood cholesterol increased
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6243 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Cardiac murmur
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Prostatic specific antigen increased
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Heart rate increased
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Heart rate irregular
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood glucose increased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Weight increased
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood creatinine increased
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood potassium increased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Glycosylated haemoglobin increased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Haemoglobin decreased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood pressure decreased
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood urine present
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood potassium decreased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood testosterone decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood uric acid increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Chest X-ray abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Intraocular pressure increased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood glucose decreased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood pressure abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood sodium decreased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Bone density decreased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Helicobacter test positive
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Liver function test increased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Occult blood positive
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Oxygen saturation decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Platelet count decreased
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Rheumatoid factor increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
SARS-CoV-2 antibody test positive
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Serum ferritin decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Urine output increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Vitamin B12 decreased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Allergy test positive
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Amylase increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Antinuclear antibody positive
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Biopsy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Biopsy breast
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood creatine increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood glucose abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood immunoglobulin E increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood immunoglobulin G decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood iron increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood pressure diastolic increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood pressure systolic increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood test abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood thyroid stimulating hormone decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood thyroid stimulating hormone increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Blood triglycerides increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Body temperature decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Brain natriuretic peptide increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Breast scan abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Breath sounds abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
C-reactive protein increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Carcinoembryonic antigen increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Colonoscopy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Computerised tomogram thorax abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Cystoscopy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Electrocardiogram T wave abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Electroencephalogram abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Glomerular filtration rate decreased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
HIV test positive
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Haemoglobin increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Hepatic enzyme increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Hepatitis B surface antibody positive
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Influenza B virus test positive
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
International normalised ratio increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Investigation abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Lipase increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Lipids abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Occult blood
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Pulse abnormal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Respiratory rate increased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Sputum abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Total lung capacity decreased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
Transaminases increased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Investigations
White blood cell count decreased
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.17%
21/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6226 • Number of events 23 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.24%
15/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.15%
19/12503 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.09%
11/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6226 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.07%
9/12503 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanocytic naevus
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin papilloma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer recurrent
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenoma
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign breast neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of adrenal gland
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign soft tissue neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dysplastic naevus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrous histiocytoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypergammaglobulinaemia benign monoclonal
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Throat cancer
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma gastric
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoid cystic carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoma benign
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell type acute leukaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basosquamous carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign hepatic neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of bladder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of thyroid gland
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder papilloma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer metastatic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer recurrent
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour pulmonary
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 1
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ear neoplasm malignant
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type)
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibroadenoma of breast
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder adenocarcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal stromal tumour
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of bone
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of liver
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of skin
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hairy cell leukaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High-grade B-cell lymphoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal papillary mucinous neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal proliferative breast lesion
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive breast carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratoacanthoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large intestine benign neoplasm
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip neoplasm malignant stage unspecified
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma of breast
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage III
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lung
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Monoclonal gammopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous breast carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibroma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ocular melanoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oral papilloma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary cystadenoma lymphomatosum
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Polycythaemia vera
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage I
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage II
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage IV
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic adenoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal adenocarcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal adenoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer metastatic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal hamartoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skull base tumour
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer limited stage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spindle cell sarcoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of head and neck
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer metastatic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid neoplasm
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine cancer
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Depression
|
0.42%
52/12503 • Number of events 52 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.29%
18/6226 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6243 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Insomnia
|
0.30%
37/12503 • Number of events 37 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6226 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6243 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Anxiety
|
0.15%
19/12503 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.40%
25/6226 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.37%
23/6243 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Sleep disorder
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Stress
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Confusional state
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Attention deficit hyperactivity disorder
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Restlessness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Abnormal dreams
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Irritability
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Panic attack
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Alcoholism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Nightmare
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Persistent depressive disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Agitation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Anxiety disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Apathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Middle insomnia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Mood swings
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Obsessive-compulsive disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Poor quality sleep
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Adjustment disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Affective disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Agoraphobia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Anger
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Anhedonia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Binge eating
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Bipolar disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Disorientation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Emotional disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Generalised anxiety disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Grief reaction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Habit cough
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Libido decreased
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Major depression
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Mental status changes
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Mood altered
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Nervousness
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Neurosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Panic disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Post-traumatic stress disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Psychotic disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Schizophrenia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Sleep terror
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Somnambulism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Suicidal ideation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Psychiatric disorders
Terminal insomnia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Vertigo
|
0.38%
47/12503 • Number of events 52 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.42%
26/6226 • Number of events 26 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6243 • Number of events 20 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Ear pain
|
0.24%
30/12503 • Number of events 31 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6226 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6243 • Number of events 17 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.16%
20/12503 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.06%
7/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Cerumen impaction
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Ear discomfort
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.03%
4/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Deafness
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Deafness bilateral
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Deafness unilateral
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Eustachian tube dysfunction
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Meniere's disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Deafness neurosensory
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Tympanic membrane perforation
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Ear congestion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Ear inflammation
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Inner ear disorder
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Middle ear effusion
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Motion sickness
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Otorrhoea
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Otosclerosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Tympanic membrane disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Deafness transitory
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Ear disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Ear haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Ear pruritus
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Eustachian tube obstruction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Inner ear inflammation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Sudden hearing loss
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Ear and labyrinth disorders
Vestibular disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.13%
16/12503 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Hypertonic bladder
|
0.10%
13/12503 • Number of events 13 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Haematuria
|
0.08%
10/12503 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6243 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Pollakiuria
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6243 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Dysuria
|
0.06%
8/12503 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal cyst
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.11%
7/6226 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary retention
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal failure
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary tract inflammation
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Micturition urgency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal colic
|
0.03%
4/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal impairment
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Cystitis noninfective
|
0.02%
3/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Stress urinary incontinence
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Bladder dysfunction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Cystitis interstitial
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Lower urinary tract symptoms
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Nephropathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Nocturia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal atrophy
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urge incontinence
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary tract disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Calculus bladder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Chromaturia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Cystitis haemorrhagic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Diabetic nephropathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
End stage renal disease
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Hypotonic urinary bladder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Incontinence
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Ketonuria
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Microalbuminuria
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Polyuria
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Proteinuria
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal cyst haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal cyst ruptured
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Renal pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urethral disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary hesitation
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Renal and urinary disorders
Vesical fistula
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.26%
33/12503 • Number of events 33 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.13%
8/6226 • Number of events 8 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.34%
21/6243 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Breast mass
|
0.03%
4/12503 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Breast pain
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.08%
5/6226 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Ovarian cyst
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Vulvovaginal pruritus
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Uterine prolapse
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Atrophic vulvovaginitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Cystocele
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Postmenopausal haemorrhage
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatic mass
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Testicular pain
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Testicular swelling
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Uterine polyp
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Balanoposthitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Bartholin's cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Breast discomfort
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Coital bleeding
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Endometrial hyperplasia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Endometrial thickening
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Epididymal cyst
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Female genital tract fistula
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Genital haemorrhage
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Genital rash
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Macroorchidism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Menopausal symptoms
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Nipple pain
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Perineal rash
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatic disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Prostatic pain
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Rectocele
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Scrotal swelling
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Vaginal discharge
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Vulvovaginal discomfort
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Reproductive system and breast disorders
Vulvovaginal dryness
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.19%
24/12503 • Number of events 24 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.22%
14/6226 • Number of events 14 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6243 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.08%
10/12503 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.18%
11/6226 • Number of events 11 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.21%
13/6243 • Number of events 15 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.14%
18/12503 • Number of events 18 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6226 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Thrombocytosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Anaemia vitamin B12 deficiency
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Immune thrombocytopenia
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Lymphadenitis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Pernicious anaemia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Anaemia folate deficiency
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Anaemia macrocytic
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Antiphospholipid syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Bone marrow oedema
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Increased tendency to bruise
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Lymphadenopathy mediastinal
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Macrocytosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Normocytic anaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Polycythaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
Spleen disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Blood and lymphatic system disorders
White blood cell disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Seasonal allergy
|
0.15%
19/12503 • Number of events 19 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.26%
16/6226 • Number of events 16 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.32%
20/6243 • Number of events 21 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Drug hypersensitivity
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Hypersensitivity
|
0.04%
5/12503 • Number of events 5 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Multiple allergies
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6243 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Food allergy
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Allergy to arthropod sting
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Allergy to arthropod bite
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Allergy to chemicals
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Allergy to vaccine
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Dust allergy
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Allergy to plants
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Amyloidosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Anaphylactic reaction
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Anti-neutrophil cytoplasmic antibody positive vasculitis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Mycotic allergy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Rubber sensitivity
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Immune system disorders
Sarcoidosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Hypothyroidism
|
0.19%
24/12503 • Number of events 25 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.16%
10/6226 • Number of events 10 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.14%
9/6243 • Number of events 9 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Hyperthyroidism
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Thyroid mass
|
0.06%
7/12503 • Number of events 7 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6243 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Goitre
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Hypogonadism
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Graves' disease
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Hyperparathyroidism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.03%
2/6226 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Adrenal mass
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Autoimmune hypothyroidism
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Primary hypothyroidism
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Thyroid cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Endocrine disorders
Toxic nodular goitre
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.10%
12/12503 • Number of events 12 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.06%
4/6243 • Number of events 4 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic steatosis
|
0.05%
6/12503 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.05%
3/6226 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.10%
6/6243 • Number of events 6 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.02%
3/12503 • Number of events 3 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic mass
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic cirrhosis
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Non-alcoholic fatty liver
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Autoimmune hepatitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholangitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Gallbladder disorder
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Gallbladder polyp
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic cyst
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatic function abnormal
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Hepatomegaly
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Liver disorder
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Hepatobiliary disorders
Non-alcoholic steatohepatitis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Type V hyperlipidaemia
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Arteriovenous malformation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Epidermal naevus
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Frenulum breve
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Gilbert's syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Hydrocele
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Hypertrophic cardiomyopathy
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Porokeratosis
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Pyloric stenosis
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Tooth hypoplasia
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Congenital, familial and genetic disorders
Turner's syndrome
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Product Issues
Device breakage
|
0.02%
2/12503 • Number of events 2 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Product Issues
Device dislocation
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6226 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Social circumstances
Ex-tobacco user
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Social circumstances
Immobile
|
0.00%
0/12503 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.02%
1/6243 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
|
Social circumstances
Menopause
|
0.01%
1/12503 • Number of events 1 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6226 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
0.00%
0/6243 • Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH)
All adverse events are presented for the Exposed set, which included all participants that received at least one study intervention.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER